Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Badanie oceniające skuteczność i bezpieczeństwo doustnego podawania etrazymodu w leczeniu dorosłych uczestników z umiarkowaną do ciężkiej czynną chorobą Leśniowskiego-Crohna (CULTIVATE)

5 czerwca 2026 zaktualizowane przez: Pfizer

Wieloośrodkowe, randomizowane, prowadzone metodą podwójnie ślepej próby badanie w grupach równoległych oceniające skuteczność i bezpieczeństwo doustnego podawania etrasimodu jako terapii wprowadzającej i podtrzymującej w przypadku choroby Leśniowskiego-Crohna o nasileniu umiarkowanym do ciężkiego

Jest to badanie fazy 2/3, które obejmuje 5 badań cząstkowych zaprojektowanych w celu oceny skuteczności, bezpieczeństwa i tolerancji doustnego etrazymodu w leczeniu dorosłych uczestników z umiarkowaną do ciężkiej czynną postacią choroby Leśniowskiego-Crohna (ChLC), którzy są oporni lub nie tolerują co najmniej 1 z obecne terapie CD (tj. kortykosteroidy, leki immunosupresyjne lub leki biologiczne). Całkowity czas trwania tego badania wynosi do 282 tygodni, w tym 28-dniowy okres badań przesiewowych, okres leczenia do 274 tygodni (włączenie, przedłużenie lub okresy podtrzymujące oraz długoterminowe okresy przedłużenia) oraz 4-tygodniowa obserwacja Up Okres oceny bezpieczeństwa.

Przegląd badań

Status

Zakończony

Warunki

Szczegółowy opis

To badanie obejmuje 5 badań podrzędnych:

Badanie podrzędne A — faza 2: badanie podrzędne fazy 2, randomizowane, z podwójnie ślepą próbą, mające na celu ocenę bezpieczeństwa, tolerancji i skuteczności doustnego leczenia etrasimodem u uczestników z CD o nasileniu umiarkowanym do ciężkiego, które wspiera wybór dawki indukującej i podtrzymującej dla fazy 3. Rejestracja do badania podrzędnego A jest obecnie zamknięta.

Badanie cząstkowe 1 – faza 2: Badanie cząstkowe fazy 2b z randomizacją, podwójnie ślepą próbą, grupą kontrolną otrzymującą placebo, z różnymi dawkami w celu oceny leczenia indukcyjnego etrasimodem i wybrania dawki indukcyjnej i podtrzymującej do dalszej oceny w fazie 3. Badanie cząstkowe 1 to trwa rejestracja uczestników.

Badanie podrzędne 2 — Indukcja: Badanie podrzędne fazy 3 z randomizacją, podwójnie ślepą próbą i grupą kontrolną otrzymującą placebo, oceniające etrasimod jako terapię indukcyjną.

Badanie podrzędne 3 — leczenie podtrzymujące: Badanie podrzędne fazy 3 z randomizacją, podwójnie ślepą próbą i grupą kontrolną otrzymującą placebo, oceniające etrasimod jako terapię podtrzymującą. Uczestnicy z badania uzupełniającego 1 i badania uzupełniającego 2 zostaną zapisani do badania uzupełniającego 3.

Badanie podrzędne 4 — Przedłużenie długoterminowe: Badanie podrzędne dotyczące długoterminowego przedłużenia dla uczestników, którzy ukończyli co najmniej 52 tygodnie leczenia. Uczestnicy z badania cząstkowego 3 i badania cząstkowego A mają zostać zapisani do badania cząstkowego 4.

Typ studiów

Interwencyjne

Zapisy (Rzeczywisty)

379

Faza

  • Faza 2
  • Faza 3

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Lokalizacje studiów

    • Free State
      • Bloemfontein, Free State, Afryka Południowa, 9301
        • Dr W Simmonds (Gastroenterology Department)
    • Gauteng
      • Benoni, Gauteng, Afryka Południowa, 1501
        • Worthwhile Clinical Trials
      • Benoni, Gauteng, Afryka Południowa, 1500
        • Dr K Rahman (OTC and Opthalmoscopy)
      • Benoni, Gauteng, Afryka Południowa, 1500
        • Lakeview Hospital radiology (Radiology)
      • Benoni, Gauteng, Afryka Południowa, 1500
        • Worthwhile Clinical trials (PFT)
      • Centurion, Gauteng, Afryka Południowa, 0157
        • Dr E Meyer & Partners, Centurion Eye Hospital (OTC and Opthalmoscopy)
      • Centurion, Gauteng, Afryka Południowa, 0157
        • Dr Jorg Reichenberger (Endoscopy)
      • Centurion, Gauteng, Afryka Południowa, 0157
        • Drs Burger Radiologists Inc (X-ray/CT)
      • Centurion, Gauteng, Afryka Południowa, 0157
        • Johese Clinical Research, Unitas Hospital
      • Johannesburg, Gauteng, Afryka Południowa, 2193
        • Wits Clinical Research
      • Kempton Park, Gauteng, Afryka Południowa, 1619
        • Clinresco Centres (Pty) Ltd
      • Kempton Park, Gauteng, Afryka Południowa, 1619
        • Burger Radiology (Radiology)
      • Kempton Park, Gauteng, Afryka Południowa, 1619
        • Dr KJP Lubuya (OCT and Opthalmology)
      • Kempton Park, Gauteng, Afryka Południowa, 1619
        • Prof O Mwantembe (Endoscopy)
      • Pretoria, Gauteng, Afryka Południowa, 0002
        • Emmed Research
      • Springs, Gauteng, Afryka Południowa, 1559
        • Dr K Rahman(OTC and Opthalmoscopy)
      • Sunninghill, Gauteng, Afryka Południowa, 2196
        • Dr I Moola (Endoscopy)
    • Western Cape
      • Cape Town, Western Cape, Afryka Południowa, 7405
        • Dr Peter Chapman (PFT + DLCO)
      • Cape Town, Western Cape, Afryka Południowa, 7441
        • Dr Chris Stander (OCT)
      • Cape Town, Western Cape, Afryka Południowa, 7441
        • Morton & Partners Radiologists (Radiology)
      • Cape Town, Western Cape, Afryka Południowa, 7441
        • Spoke Research Inc. Room 109
    • Prov. de Buenos Aires
      • Ciudadela, Prov. de Buenos Aires, Argentyna, 1702
        • Instituto Medico Elsa Perez(I.M.E.P)
      • Ciudadela, Prov. de Buenos Aires, Argentyna, B1702GIK
        • Instituto Medico Elsa Perez (I.M.E.P.) (Local Lab)
      • Ciudadela, Prov. de Buenos Aires, Argentyna, B1702GIK
        • Instituto Medico Elsa Perez (I.M.E.P.) (Pharmacy)
      • Hurlingham, Prov. de Buenos Aires, Argentyna, B1686NCI
        • Estudio de La Vision (OCT, Ophthalmoscopy)
    • Santa Fe Province
      • Rosario, Santa Fe Province, Argentyna, S2000DEJ
        • Instituto Medico de la Fundacion Estudios Clinicos
      • Rosario, Santa Fe Province, Argentyna, S2000AUC
        • Gastroenterologia Rosario (Endoscopy)
      • Rosario, Santa Fe Province, Argentyna, S2000CTC
        • Microcirugia Ocular SA (OCT, Ophthalmoscopy)
      • Rosario, Santa Fe Province, Argentyna, S2000KZD
        • Consultorios extemos de Sanatorio Parque (PFT with DLCO, Pulmonar Functional Test with DLCO)
    • Tucumán Province
      • San Miguel de Tucumán, Tucumán Province, Argentyna, T4000AXL
        • Centro de Investigaciones Médicas Tucuman
    • New South Wales
      • Macquarie University, New South Wales, Australia, 2109
        • Macquarie University Hospital
      • Macquarie University, New South Wales, Australia, 2109
        • Macquarie University Hospital Pharmacy
      • Macquarie University, New South Wales, Australia, 2109
        • Macquarie Respiratory Services
      • Macquarie University, New South Wales, Australia, 2109
        • Macquarie University Hospital Clinical Trials
      • Macquarie University, New South Wales, Australia, 2109
        • MQ Health Ophthalmology
    • Queensland
      • Brisbane, Queensland, Australia, 4029
        • Royal Brisbane & Women's Hospital
      • North Mackay, Queensland, Australia, 4740
        • Coral Sea Clinical Research Institute
    • Victoria
      • Bellfield, Victoria, Australia, 3081
        • MCES Practice Pty Ltd operating as Comprehensive Eye Surgeons
      • Epping, Victoria, Australia, 3076
        • The Northern Hospital
      • Heidelberg, Victoria, Australia, 3084
        • Austin Hospital
      • Melbourne, Victoria, Australia, 3011
        • Vision Eye Institute
      • Melbourne, Victoria, Australia, 3011
        • Footscray Hospital
      • Parkville, Victoria, Australia, 3050
        • The Royal Melbourne Hospital
      • Rosanna, Victoria, Australia, 3084
        • Heidelberg Eye Clinic
    • Western Australia
      • Murdoch, Western Australia, Australia, 6150
        • Fiona Stanley Hospital
      • Nedlands, Western Australia, Australia, 6009
        • Lions Eye Institute Limited
      • O'Connor, Western Australia, Australia, 6163
        • The trustee for The RTS Unit Trust trading as Respiratory Testing Services
      • Graz, Austria, 8036
        • LKH Universitats-Klinikum Graz
      • Innsbruck, Austria, A-6020
        • Medical University Innsbruck, Internal Medicine Ⅰ
      • Vienna, Austria, 1090
        • AKH Wien- Universitatsklinik fiir Innere Medizin III
      • Vienna, Austria, 1090
        • Univ.-Professor Dr. Mehrdad Baghestanian
      • Vienna, Austria, 1090
        • AKH Wien- Universitatsklinik fur Innere Medizin III
      • Ghent, Belgia, 9000
        • Universitair Ziekenhuis Gent
      • Ghent, Belgia, 9000
        • AZ Maria-Middelares
      • Leuven, Belgia, 3000
        • Universitaire Ziekenhuizen Leuven
      • Roeselare, Belgia, 8800
        • Campus Brugsesteenweg
      • Roeselare, Belgia, 8800
        • Campus Rumbeke
      • Torhout, Belgia, 8820
        • Campus Rembert Torhout
      • Yvoir, Belgia, 5530
        • Centre Hospitalier Universitaire UCL Namur - Site Godinne
      • Homyel, Białoruś, 246029
        • Institution "Gomel Regional Clinical Hospital"
      • Minsk, Białoruś, 220096
        • Health care Institution "10th City Clinical Hospital"
      • Mogilev, Białoruś, 212018
        • Health Care Institution "Mogilev Hospital #1"
      • Vitebsk, Białoruś, 210037
        • Health Care Institution "Vitebsk Regional Clinical Hospital"
      • Vitebsk, Białoruś, 210604
        • Healthcare Institution "Vitebsk Regional Clinical Specialized Center"
      • Sofia, Bułgaria, 1527
        • UMHAT "Tsaritsa Yoanna-ISUL" EAD
      • Sofia, Bułgaria, 1431
        • "DCC Alexandrovska", EOOD
      • Sofia, Bułgaria, 1606
        • ,,University multiprofile hospital for active treatment and emergency medicine N.I. Pirogov" EAD
    • RM
      • Santiago, RM, Chile, 8330034
        • Centro de Investigaciones Clinicas de la Universidad Catolica
    • Santiago Metropolitan
      • Santiago, Santiago Metropolitan, Chile, 7620157
        • Clinica Universidad de Los Andes
      • Santiago, Santiago Metropolitan, Chile, 8330336
        • CeCim Biocinetic
      • Zagreb, Chorwacja, 10000
        • University Hospital Center Zagreb
      • Horažďovice, Czechy, 341 01
        • MUDr. Jaroslava Skalova
      • Hradec Králové, Czechy, 500 12
        • Hepato-gastroenterologie HK, s.r.o.
      • Hradec Králové, Czechy, 500 12
        • VISUS, spol s.r.o.
      • Klatovy, Czechy, 339 01
        • GASTRO JeKa, s.r.o.
      • Klatovy, Czechy, 339 01
        • Klatovska nemocnice a.s.
      • Olomouc, Czechy, 779 00
        • PreventaMed s.r.o.
      • Olomouc, Czechy, 779 00
        • Ocni ordinace Olomouc
      • Olomouc, Czechy, 779 00
        • MUDr. Pavlina Kazinotova s.r.o.
      • Aalborg, Dania, 9000
        • Aalborg University Hospital, Department of Medical Gastroenterology, Medicinerhuset
      • Hvidovre, Dania, 2650
        • Hvidovre University Hospital
      • Alexandria, Egipt, 21131
        • Alexandria Clinical Research Center , Faculty of Medicine , Alexandria University
      • Cairo, Egipt
        • National Hepatology and Tropical Medicine Research Institute
      • Cairo, Egipt, 11556
        • Ain Shams University Hospital
      • Cairo, Egipt
        • Air Force Specialized Hospital(AFSH)
      • Cairo, Egipt
        • Cairo University , Kasr Al Aini Hospital
      • Dakahlia, Egipt
        • Egyptian Liver Research Institute and Hospital ( ELRIAH)
      • Giza, Egipt
        • Theodor Bilharz Research Institute Research Ethics Committee
      • Menofeya, Egipt, 32511
        • National Liver Institute
      • Amiens, Francja, 80054
        • CHU Amiens Picardie
      • Clermont-Ferrand, Francja, 63000
        • Chu Gabriel Montpied
      • Clermont-Ferrand, Francja, 63000
        • CHU De Clermont Ferrand - Hopital Estaing
      • Grenoble, Francja, 38043
        • CHU Grenoble Alpes - Hopital Michallon
      • Grenoble, Francja, 38043
        • Endoscopy: CHU Grenoble Alpes- Hopital Michallon
      • La Roche-sur-Yon, Francja, 85925
        • CHD Vendee, Unite de Recherche Clinique
      • Lille, Francja, 59037
        • CHU de Lille - Hôpital Claude Huriez
      • Lille, Francja, 59037
        • Optical Coherence Tomography and Ophthalmology CHU de Lille Hopital Roger Salengro
      • Lille, Francja, 59037
        • Pulmonary Function Test CHU Lille, Institut Coeur Poumon
      • Montpellier, Francja, 34295
        • CHU Saint-Eloi
      • Montpellier, Francja, 34295
        • Hopital Saint-Eloi - Pole Digestif - Hgea Recherche Clinique - Rdc
      • Nice, Francja, 06202
        • CHU de Nice, Hopital 1'Archet 2
      • Reims, Francja, 51100
        • Hopital Maison Blanche, CHU DE REIMS
      • Reims, Francja, 51092
        • Hopital Robert Debre
      • Reims, Francja, 51100
        • Hopital Robert Debre CHU DE REIMS
      • Saint-Etienne, Francja, 42055
        • CHU Saint Etienne - Hôpital Nord
      • Saint-Priest-en-Jarez, Francja, 42270
        • Optical Coherence Tomography and Ophthalmology
      • Saint-Priest-en-Jarez, Francja, 42270
        • Pulmonary Function Test
      • Toulouse, Francja, 31059
        • Hopital Rangueil
      • Toulouse, Francja, 31300
        • Hopital Purpan PPR pole cephalique
      • Vandœuvre-lès-Nancy, Francja, 54511
        • CHRU Nancy Brabois
      • Alexandroupoli, Grecja, 681 00
        • University General Hospital of Alexandroupoli
      • Athens, Grecja, 10676
        • General Hospital of Athens "Evangelismos"
    • Crete
      • Heraklion, Crete, Grecja, 71500
        • Univerisity General Hospital of Heraklion
      • Tbilisi, Gruzja, 0160
        • LTD Aversi Clinic
      • Tbilisi, Gruzja, 0159
        • LTD Institute of Clinical Cardiology
      • Tbilisi, Gruzja, 0160
        • JSC Infectious Diseases, AIDS and Clinical Immunology Research Center
      • Tbilisi, Gruzja, 0160
        • LTD Academician Nikoloz Kipshidze Central University Clinic
      • Tbilisi, Gruzja, 0172
        • Malkhaz Katsiashvili Multiprofile Emergency Medicine Center, LTD
      • Tbilisi, Gruzja, 0179
        • LTD Medical Center "CITO"
      • Las Palmas de Gran Canaria, Hiszpania, 35010
        • Hospital Universitario de Gran Canaria Dr. Negrín
      • Madrid, Hiszpania, 28046
        • Hospital Universitario La Paz
    • Ciudad REAL
      • Tomellso, Ciudad REAL, Hiszpania, 13700
        • Hospital General de Tomelloso
      • Amsterdam, Holandia, 1105 AZ
        • Academic Medical Centre
      • Utrecht, Holandia, 3584 CX
        • UMC Utrecht
      • Kochi, Indie, 682027
        • Aster Medcity, Aster DM Healthcare Ltd.
    • Gujarat
      • Surat, Gujarat, Indie, 395002
        • Surat Institute of Digestive Sciences
    • Haryana
      • Gurugram, Haryana, Indie, 122002
        • Fortis Memorial Research Institute
    • Maharashtra
      • Nagpur, Maharashtra, Indie, 440010
        • Midas Multispeciality Hospital Pvt. Ltd
    • Rajasthan
      • Jaipur, Rajasthan, Indie, 302001
        • S. R. Kalla Memorial Gastro & General Hospital
      • Afula, Izrael, 1834111
        • Haemek Medical Center
      • Jerusalem, Izrael, 9103102
        • Shaare Zedek Medical Center
      • Ramat Gan, Izrael, 5262000
        • Chaim Sheba Medical Center
      • Tel Aviv, Izrael, 6423906
        • Tel Aviv Sourasky Medical Center
    • Chiba
      • Kashiwa-shi, Chiba, Japonia, 277-0871
        • Kokikai Tsujinaka Hospital Kashiwanoha
      • Nagareyama-shi, Chiba, Japonia, 270-0116
        • Ishii Eye Clinic
    • Fukuoka
      • Kitakyushu-shi, Fukuoka, Japonia, 807-8555
        • Hospital of the University of Occupational and Environmental Health
      • Kitakyusyu-shi, Fukuoka, Japonia, 802-8561
        • Kitakyushu Municipal Medical Center
    • Ibaraki
      • Toride-shi, Ibaraki, Japonia, 302-0014
        • Matsumoto Eye Clinic
    • Kagoshima-ken
      • Kagoshima, Kagoshima-ken, Japonia, 892-0846
        • Sameshima Hospital
      • Kagoshima, Kagoshima-ken, Japonia, 892-0824
        • Jiaikai Idzuro Imamura Hospital
      • Kagoshima, Kagoshima-ken, Japonia, 890-0062
        • Kagoshima Kouseiren Hospital
      • Kagoshima, Kagoshima-ken, Japonia, 892-0825
        • Sameshima Eye Clinic
    • Kumamoto
      • Kumamoto, Kumamoto, Japonia, 861-8520
        • Japanese Red Cross Kumamoto Hospital
    • Saga-ken
      • Saga, Saga-ken, Japonia, 849-8501
        • Saga University Hospital
    • Tokyo
      • Shinjuku-ku, Tokyo, Japonia, 169-0073
        • Japan Community Health Care Organization Tokyo Yamate Medical Center
    • Quebec
      • Montreal, Quebec, Kanada, H3G 1A4
        • McGill University Health Centre - Montreal General Hospital (Electrocardiogram Clinic)
      • Montreal, Quebec, Kanada, H3G 1A4
        • McGill University Health Centre - Montreal General Hospital (Endoscopy Clinic)
      • Montreal, Quebec, Kanada, H3G 1A4
        • McGill University Health Centre - Montreal General Hospital (Pharmacy)
      • Montreal, Quebec, Kanada, H3G 1A4
        • McGill University Health Centre - Montreal General Hospital (Radiology)
      • Montreal, Quebec, Kanada, H3G 1A4
        • McGill University Health Centre - Montreal General Hospital (Research Site)
      • Montreal, Quebec, Kanada, H4A 3J1
        • Centre for Innovative Medicine - Research Institute of the McGill University Health Centre(Pulmonary
      • Montreal, Quebec, Kanada, H4P 2S4
        • Eye Health MD (Ophthalmology)
    • Quindío Department
      • Armenia, Quindío Department, Kolumbia, 630004
        • IPS Fundacion Cardiomet CEQUIN
    • Valle del Cauca Department
      • Cali, Valle del Cauca Department, Kolumbia, 760035
        • Centro de lnvestigaciones Clinicas S.A.S
      • Daegu, Korea Południowa, 41404
        • Kyungpook National University Chilgok Hospital
      • Daegu, Korea Południowa, 41944
        • Kyungpook National University Hospital
      • Daegu, Korea Południowa, 41944
        • Endoscopy Facility in kyungpook National University Hospital
      • Daegu, Korea Południowa, 41944
        • OCT Facility In kyungpook National University Hospital
      • Daegu, Korea Południowa, 41944
        • PFT Facility in Kyungpook National University Hospital
      • Daejeon, Korea Południowa, 34943
        • The Catholic University of Korea, Daejeon ST. Mary's Hospital
      • Incheon, Korea Południowa, 21565
        • Gachon University Gil Medical Center
      • Seongnam-si, Korea Południowa, 13496
        • CHA University Bundang CHA Hospital
      • Seoul, Korea Południowa, 06273
        • Gangnam Severance Hospital, Yonsei University Health System
      • Seoul, Korea Południowa, 06973
        • Chung-Ang University Hospital
      • Seoul, Korea Południowa, 02447
        • Kyunghee University Medical Center
    • Gyeonggi-do
      • Goyang-si, Gyeonggi-do, Korea Południowa, 10326
        • Dongguk University Ilsan Hospital
      • Beirut, Liban, 166830
        • Hotel Dieu de France Hospital
      • Beirut, Liban, 1100 2807
        • Saint George University Hospital Medical Center
      • Beirut, Liban, 113-6044
        • Rafik Hariri University Hospital
      • Saida, Liban
        • Hammoud Hospital University Medical Center
      • Tripoli, Liban
        • Nini Hospital s.a:l
      • Vilnius, Litwa, LT-08661
        • Vilnius University Hospital Santaros Klinikos
      • Kuala Lumpur, Malezja, 59100
        • University Malaya Medical Centre
      • Chihuahua City, Meksyk, 31203
        • Scientia Investigacion Clinica S.C.
      • Chihuahua City, Meksyk, 31020
        • Sanatorio Palmore A.C.
      • Chihuahua City, Meksyk, 31203
        • Vista Lasser de Chihuahua S.C.
      • Chihuahua City, Meksyk, 31283
        • Servicios Hospitalarios de México, S.A. de C.V.
      • Veracruz, Meksyk, 91900
        • FAICIC S. de R.L. de C.V.
      • Veracruz, Meksyk, 91910
        • Gabinete de Diagnostico COVADONGA
      • Veracruz, Meksyk, 91918
        • Alberto Collado Solorzano (Clinica Vision)
    • Jalisco
      • Guadalajara, Jalisco, Meksyk, 44130
        • Centro de Investigacion Medico Biologica Y Terapia Avanzada S.C.
      • Guadalajara, Jalisco, Meksyk, 44600
        • Global Glaucoma Institute
      • Guadalajara, Jalisco, Meksyk, 44600
        • Video Endoscopia Americas
      • Guadalajara, Jalisco, Meksyk, 44670
        • Comercializadora Winco S.A. de C.V.
    • Veracruz
      • Boca del Rio, Veracruz, Meksyk, 94299
        • Cirugia y Gastro de Veracruz S.A. de C.V. (Progastro)
      • Chisinau, Moldova, 2005
        • "Sf. Arhanghel Mihail" Municipal Clinical Hospital, Department of Gastroenterology
      • Chisinau, Moldova, MD2025
        • PMSI Republican Clinical Hospital "Timofei Mosneaga", Department of Colorectal Surgery
      • Chisinau, Moldova, MD2025
        • PMSI Republican Clinical Hospital "Timofei Mosneaga", Department of Gastroenterology
      • Chisinau, Moldova, MD2025
        • PMSI Republican Clinical Hospital "Timofei Mosneaga", Outpatient Department
      • Augsburg, Niemcy, 86156
        • Universitaetsklinikum Augsburg
      • Brandenburg an der Havel, Niemcy, 14770
        • Staedtisches Klinikum Brandenburg
      • Frankfurt, Niemcy, 60431
        • Prof. Dr. med. Dr. med. Habil. Jens Buhren, FEBO
      • Frankfurt am Main, Niemcy, 60431
        • Agaplesion Markus Krankenhaus
      • Hamburg, Niemcy, 20251
        • HaFCED e.K. - Hamburgisches Forschungsinstitut für chronisch entzündliche Darmerkrankungen
      • Jena, Niemcy, 07747
        • Universitaetsklinikum Jena
      • Jena, Niemcy, 07747
        • OCT/Ophtalmoscopy address: Universitaetsklinikum Jena
      • Jena, Niemcy, 07747
        • PFT address: Universitaetsklinikum Jena
      • Kassel, Niemcy, 34121
        • PFT address: Praxis fur Pneumologie und Allergologie
      • Kassel, Niemcy, 34177
        • OCT/Ophtalmoscopy address: Augenarztpraxis Dr. Karola Hassan
      • Kiel, Niemcy, 24105
        • Nordblick Augenklinik
      • Kiel, Niemcy, 24105
        • Universitatsklinikum Schleswig-Holstein- Campus Kiel
      • Nürtingen, Niemcy, 72622
        • Dr. Irina Hasewinkel
      • Nürtingen, Niemcy, 72622
        • Medius Klinik Nuertingen
    • Hassen
      • Kassel, Hassen, Niemcy, 34117
        • Gastroenterologie Opernstraβe
      • Bystra, Polska, 43-360
        • Centrum Pulmonologii i Torakochirurgii w Bystrej (DLCO)
      • Karkow, Polska, 31-156
        • Specjalistyczne Gabinety Lekarskie LANDA
      • Krakow, Polska, 30-033
        • Centre De La Vision Centrum Okulistyczne(OCT, Ophthalmoscopy)
      • Krakow, Polska, 30-307
        • Medicina (Endoscopy)
      • Krakow, Polska, 31-153
        • Centrum Medyczne EVITA(Endoscopy)
      • Lodz, Polska, 90-752
        • IP Clinic Sp. z o.o.
      • Lodz, Polska, 90-338
        • Centrum Medyczne "Ksiezy Mlyn" (OCT, Ophtalmoscopy)
      • Lodz, Polska, 93-513
        • Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatolog i im. M. Kopernika w Lodzi
      • Lodz, Polska, 90-338
        • (Centrum Medyczne Ksiezy Mlyn (OCT and Ophthalmoscopy)
      • Lodz, Polska, 90-644
        • AMICARE Sp. z o.o. sp.k
      • Lodz, Polska, 91-053
        • Centra Medyczne Medyceusz (DLCO)
      • Lodz, Polska, 92-551
        • Salve Health Care Sp. o.o., (PFT and Endoscopy)
      • Nowy Targ, Polska, 34-400
        • Allmedica Badania Kliniczne Sp. z o.o. Sp. k.
      • Oświęcim, Polska, 32-600
        • Medicome Sp. Z O.O
      • Piotrkow Trybunalski, Polska, 97-300
        • Przychodnia Okulistyczna "Oculus" Barbara Cybulska (OCT, Ophtalmoscopy)
      • Piotrkow Trybunalski, Polska, 97-300
        • Samodzielny Szpital Wojewodzki im. Mikolaja Kopernika (Endoscopy)
      • Piotrokow Trybunalski, Polska, 97-300
        • Trialmed CRS
      • Poznan, Polska, 60-529
        • Solurmed Centrum Medyczne
      • Poznan, Polska, 60-538
        • OCU Service Mikolaj Meller Sp.j.(OCT, Ophtalmoscopy)
      • Rzeszów, Polska, 35-326
        • Centrum Medyczne Medyk
      • Rzeszów, Polska, 35-055
        • Kliniczny Szpital Wojewodzki Nr 1 im. Fryderyka Chopina w Rzeszowie (Ophthalmpscopy)
      • Rzeszów, Polska, 35-241
        • Podkarpackie Centrum Chorob Plue w Rzeszowie (DLCO)
      • Strzegom, Polska, 58-150
        • Strzegomskie Centrum Medyczno - Diagnostyczne Sp. z o.o. (Endoscopy)
      • Swidnica, Polska, 58-100
        • DC-MED
      • Swidnica, Polska, 58-100
        • Centrum Medyczne EZ-MEDICA (OCT, Ophtalmoscopy)
      • Swidnica, Polska, 58-100
        • Szpital "Latawiec" -Poradnia Gruzlicy i Chorob Pluc (PFT)
      • Warsaw, Polska, 00-635
        • Centrum Zdrowia MDM
      • Warsaw, Polska, 00-631
        • Centrum Zdrowia MDM (OCT,opthalmoscopy)
      • Warsaw, Polska, 01-138
        • Instytut Gruzlicy i Chorob Pluc(DLCO)
      • Warsaw, Polska, 02-653
        • Endoterapia PFG (Endoscopy)
      • Warsaw, Polska, 02-653
        • Instytut Oka (OCT, Ophtalmoscopy)
      • Warsaw, Polska, 03-712
        • Specjalistyczne Gabinety Lekarskie Body Clinic
      • Warsaw, Polska, 03-731
        • Centrum Okulistyczne JASKRA (OCT, Ophthalmoscopy)
      • Warsaw, Polska, 04-141
        • Wojskowy lnstytut Medyczny (PFT)
      • Wroclaw, Polska, 60-681
        • EuroMediCare Szpital Specjalistyczny z Przychodniit (Endoscopy)
    • Greater Poland Voivodeship
      • Poznan, Greater Poland Voivodeship, Polska, 60-681
        • NSZOZ Termedica
      • Kemerovo, Rosja, 650066
        • SAIH "Kemerovo Regional Clinical Hospital"
      • Novosibirsk, Rosja, 630005
        • LLC "SibNovoMed"
      • Novosibirsk, Rosja, 630007
        • Gastrocenter
      • Novosibirsk, Rosja, 630007
        • LLC "Novosibirskiy Gastrocentr''
      • Novosibirsk, Rosja, 630084
        • Hospital #12
      • Novosibirsk, Rosja, 630091
        • LLC "Siberian Center for Prevention and Treatment of Myopia Eye"
      • Novosibirsk, Rosja, 630099
        • Joint Stock Company Medical Center "AVICENNA"
      • Omsk, Rosja, 644013
        • BHI of Omsk region "Clinical Oncology Dispensary"
      • Omsk, Rosja, 644024
        • Clinicodiagnostic Center "Ultramed"
      • Omsk, Rosja, 644070
        • Medical center "Intervzglyad"
      • Saint Petersburg, Rosja, 191015
        • FSBI of Higher Education " North-Western Medical University n.a.I.I. Mechnikov '' of MoH RF
      • Saint Petersburg, Rosja, 195067
        • FSBI of Higher Education "North-Western Medical University n.a.I.I. Mechnikov'' of MoH RF
      • Stavropol, Rosja, 355017
        • Autonomous Noncommercial Medical Organization "Stavropol Regional Clinical
    • Stavropol Kray
      • Pyatigorsk, Stavropol Kray, Rosja, 357502
        • LLC "Polyclinic of ultrasonography 4D"
      • Bucharest, Rumunia, 012015
        • SC Centrul Medical Medicum SRL, Specialitatea Gastroenterologie
      • Bucharest, Rumunia, 022328
        • Institutul Clinic Fundeni, Centrul de Gastroenterologie si Hepatologie
    • JUD. CLUJ
      • Cluj-Napoca, JUD. CLUJ, Rumunia, 400006
        • Spitalul Clinic Judetean de Urgenta Cluj Napoca
    • Jud.constanta
      • Constanța, Jud.constanta, Rumunia, 900591
        • Centrul de Diagnostic si Tratament Affidea, Specialitatea Medicina Interna
      • Belgrade, Serbia, 11000
        • Clinical Center Zvezdara
    • Alabama
      • Dothan, Alabama, Stany Zjednoczone, 36301
        • Digestive Health Specialists
      • Dothan, Alabama, Stany Zjednoczone, 36301
        • Dothan Eyecare-Dr. Brent McKinley (OCT Location)
      • Dothan, Alabama, Stany Zjednoczone, 36301
        • Center for Digestive Health (Endoscopy Location)
      • Dothan, Alabama, Stany Zjednoczone, 36301
        • Pulmonary Associates (PFT Location)
      • Dothan, Alabama, Stany Zjednoczone, 36305
        • Flowers Hospital (Imaging Location)
      • Mobile, Alabama, Stany Zjednoczone, 36608
        • Digestive Health Specialists (Satellite Clinic Location)
      • Mobile, Alabama, Stany Zjednoczone, 36608
        • Premier Medical Group East (Opthalmology & Optometry Facility)
      • Mobile, Alabama, Stany Zjednoczone, 36608
        • Pulmonary Associates (Chest X-Ray & PFT Facility)
      • Mobile, Alabama, Stany Zjednoczone, 36608
        • Surgicare of Mobile (Endoscopy & Biopsy Facility)
    • Arizona
      • Peoria, Arizona, Stany Zjednoczone, 85381
        • Arizona Retina Institute/ Phoenix Retina Associates(OCT)
      • Peoria, Arizona, Stany Zjednoczone, 85381
        • SimonMed Imaging (Imaging)
      • Sun City, Arizona, Stany Zjednoczone, 85351
        • Sun City Endoscopy Center (Endoscopy)
    • California
      • Apple Valley, California, Stany Zjednoczone, 92307
        • Om Research LLC
      • Apple Valley, California, Stany Zjednoczone, 92307
        • Victor Valley Advanced Imaging
      • La Jolla, California, Stany Zjednoczone, 92037
        • UCSD lnvestigational Drug Service Pharmacy
      • La Jolla, California, Stany Zjednoczone, 92093
        • Shiley Eye Institute (OCT)
      • La Jolla, California, Stany Zjednoczone, 92037
        • Koman Family Outpatient Pavilion (ENDO)
      • La Jolla, California, Stany Zjednoczone, 92037
        • Perlman Medical Offices
      • La Jolla, California, Stany Zjednoczone, 92037
        • UCSD Clinical and Translational Research Institute
      • La Jolla, California, Stany Zjednoczone, 92037
        • UCSD Health System (Endo/PFT/DLCO)
      • Lancaster, California, Stany Zjednoczone, 93534
        • Om Research LLC
      • Lancaster, California, Stany Zjednoczone, 93534
        • A V Pediatrics, Allergy and Family Medicine - PFT
      • Lancaster, California, Stany Zjednoczone, 93534
        • Advanced Endoscopy and Pain Center - Colonoscopy
      • Lancaster, California, Stany Zjednoczone, 93534
        • Advanced Imaging Center - Chest X-Ray
      • Lancaster, California, Stany Zjednoczone, 93534
        • Antelope Valley Eye Care - Ophthalmologist
      • Lancaster, California, Stany Zjednoczone, 93534
        • AV Pediatrics Allergy and Family Medicine
      • Lancaster, California, Stany Zjednoczone, 93534
        • Jatinder S. Pruthi, MD FACG CPI
      • Murrieta, California, Stany Zjednoczone, 92563
        • United Medical Doctors
      • Victorville, California, Stany Zjednoczone, 92392
        • Retina Consultants of Southern California
      • Victorville, California, Stany Zjednoczone, 92395
        • Physicians Surgery Center
    • Colorado
      • Colorado Springs, Colorado, Stany Zjednoczone, 80907
        • Peak Gastroenterology Associates
      • Colorado Springs, Colorado, Stany Zjednoczone, 80903
        • Front Range Endoscopy Center
      • Colorado Springs, Colorado, Stany Zjednoczone, 80909
        • Colorado Springs Pulmonary Consultants, PC
      • Colorado Springs, Colorado, Stany Zjednoczone, 80909
        • The Wright Eye Center (OCT Facility)
      • Colorado Springs, Colorado, Stany Zjednoczone, 80919
        • Colorado Springs Imaging (Ultrasound and MRE Location)
    • Florida
      • Boca Raton, Florida, Stany Zjednoczone, 33487
        • Xera Med Research
      • Boynton Beach, Florida, Stany Zjednoczone, 33472
        • RecioMed Clinical Research Network, Inc
      • Brandon, Florida, Stany Zjednoczone, 33511
        • Florida Advanced Gastroenterology Center - Rahman Nakshabendi MD and Imad Nakshabendi, MD
      • Clearwater, Florida, Stany Zjednoczone, 33756
        • West Coast Endoscopy Center (Endoscopy Procedures)
      • Clearwater, Florida, Stany Zjednoczone, 33756
        • Bay Area Chest Physicians, P.A. (Pulmonary Function Test)
      • Clearwater, Florida, Stany Zjednoczone, 33761
        • Northwood Vision (Optical Coherence Tomography)
      • Clearwater, Florida, Stany Zjednoczone, 33761
        • Safety Harbor Surgery (Endoscopy Procedures)
      • Clearwater, Florida, Stany Zjednoczone, 33762
        • Gastro Florida (Regulatory Administrative Duties)
      • Coral Gables, Florida, Stany Zjednoczone, 33134
        • Beraja Medical Institute (OCT)
      • Hialeah, Florida, Stany Zjednoczone, 33012
        • Advanced Eye Center
      • Jacksonville, Florida, Stany Zjednoczone, 32256
        • Encore Borland-Groover Clinical Research
      • Jacksonville, Florida, Stany Zjednoczone, 32207
        • UF Health Imaging Center-Emerson (chest x-rays)
      • Jacksonville, Florida, Stany Zjednoczone, 32207
        • UF Health Laboratory Emerson (blood draws)
      • Jacksonville, Florida, Stany Zjednoczone, 32209
        • UF Health Jacksonville Respiratory Therapy (PFT and DLCO)
      • Jacksonville, Florida, Stany Zjednoczone, 32209
        • UF Health Jacksonville-Faculty Clinic (ileocolonoscopy and biopsy)
      • Jacksonville, Florida, Stany Zjednoczone, 32209
        • UF Health Opthalmology - Jacksonville (Ophthalmology with OCT)
      • Jacksonville, Florida, Stany Zjednoczone, 32209
        • UF Health Radiology-Jacksonville (chest x-rays)
      • Jacksonville, Florida, Stany Zjednoczone, 32216
        • Cisca Pulmonary & Critical Care (PFT Facility)
      • Jacksonville, Florida, Stany Zjednoczone, 32216
        • Nicolitz Eye Consultants (OCT Facility)
      • Jacksonville, Florida, Stany Zjednoczone, 32256
        • Borland-Groover Clinic (Endoscopy Facility)
      • Jupiter, Florida, Stany Zjednoczone, 33458
        • Jupiter Outpatient Surgery Center
      • Kissimmee, Florida, Stany Zjednoczone, 34741
        • IHS Health, LLC
      • Largo, Florida, Stany Zjednoczone, 33773
        • Lee Shettle Eye & Hearing (Ophthalmoscopy Only)
      • Miami, Florida, Stany Zjednoczone, 33133
        • Infinite Clinical Research
      • Miami, Florida, Stany Zjednoczone, 33156
        • Research Associates of South Florida
      • Miami, Florida, Stany Zjednoczone, 33176
        • Anchor Medical Research, LLC
      • Miami, Florida, Stany Zjednoczone, 33134
        • The Endoscopy Center (Endoscopy Procedure)
      • Miami, Florida, Stany Zjednoczone, 33173
        • Juan Barrio, MD (PFT when needed)
      • Miami, Florida, Stany Zjednoczone, 33133
        • Pulmonology Physicians of South Florida
      • Miami, Florida, Stany Zjednoczone, 33133
        • Reina Eye Care P.A.
      • Miami, Florida, Stany Zjednoczone, 33155
        • La Salud Research Clinic Inc.
      • Miami, Florida, Stany Zjednoczone, 33156
        • South Florida Center for Endoscopy and Digestive Disease, LLC
      • Naples, Florida, Stany Zjednoczone, 34102
        • Gastroenterology Group of Naples
      • Naples, Florida, Stany Zjednoczone, 34102
        • Gulfshore Endoscopy Center
      • Naples, Florida, Stany Zjednoczone, 34103
        • Retina Consultants of Southwest Florida OCT only
      • Naples, Florida, Stany Zjednoczone, 34109
        • Lisette Delgado Sanchez, MD PFT only
      • Orlando, Florida, Stany Zjednoczone, 32825
        • Pediatric & Adult Research Center
      • Palmetto Bay, Florida, Stany Zjednoczone, 33157
        • IMIC Inc.
      • Palmetto Bay, Florida, Stany Zjednoczone, 33157
        • IMIC Inc
      • Port Orange, Florida, Stany Zjednoczone, 32127
        • Advanced Medical Research Center
      • Seminole, Florida, Stany Zjednoczone, 33777
        • Bardmoor GastroEnterology
      • South Miami, Florida, Stany Zjednoczone, 33143
        • Larkin Community Hospital (Endoscopy Procedure)
      • St. Petersburg, Florida, Stany Zjednoczone, 33705
        • St. Petersburg Endoscopy Center (Endoscopy Procedures)
      • St. Petersburg, Florida, Stany Zjednoczone, 33707
        • Pasadena Center for Asthma and Lung Disorders (PFT and DLCO Only)
      • St. Petersburg, Florida, Stany Zjednoczone, 33709
        • Bay Area Endoscopy and Surgery Center (Endoscopy only)
      • St. Petersburg, Florida, Stany Zjednoczone, 33709
        • Theia Clinical Research, LLC
      • St. Petersburg, Florida, Stany Zjednoczone, 33710
        • Advanced Research Institute Inc.(IP and PFT)
      • Sun City Center, Florida, Stany Zjednoczone, 33573
        • Absolute Surgical Specialist - Craig Amshel, MD
      • Tampa, Florida, Stany Zjednoczone, 33612
        • USF Health Morsani Center for Advanced Healthcare
      • Tampa, Florida, Stany Zjednoczone, 33606
        • USF Health South Tampa Center for Advanced Healthcare
      • Tampa, Florida, Stany Zjednoczone, 33609
        • GCP Clinical Research,LLC
      • Tampa, Florida, Stany Zjednoczone, 33609
        • South Tampa Surgery Center
      • Tampa, Florida, Stany Zjednoczone, 33609
        • Newsome Eye Specialist (OCT Procedures Only)
      • Tampa, Florida, Stany Zjednoczone, 33606
        • Lab - Processing/ Storage
      • Tampa, Florida, Stany Zjednoczone, 33609
        • LoCicero Medical Group
    • Georgia
      • Atlanta, Georgia, Stany Zjednoczone, 30342
        • Atlanta Gastroenterology Associates
      • Atlanta, Georgia, Stany Zjednoczone, 30309
        • Digestive Healthcare of Georgia
      • Atlanta, Georgia, Stany Zjednoczone, 30324
        • Ross Eyecare - Opthalmoscopy and OCT
      • Atlanta, Georgia, Stany Zjednoczone, 30342
        • Atlanta Gastroenterology Associates (endoscopy only)
      • Atlanta, Georgia, Stany Zjednoczone, 30342
        • Atlanta Gastroenterology Associates(IP only)
      • Atlanta, Georgia, Stany Zjednoczone, 30309
        • Peachtree Allergy and Asthma Clinic - Chest X-rays and PFTs
    • Illinois
      • Arlington Heights, Illinois, Stany Zjednoczone, 60005
        • GI Alliance
      • Arlington Heights, Illinois, Stany Zjednoczone, 60005
        • Northwest Endoscopy Center (Endoscopy)
      • Gurnee, Illinois, Stany Zjednoczone, 60031
        • GI Alliance (PFT)
      • Gurnee, Illinois, Stany Zjednoczone, 60031
        • Illinois Gastroenterology Group-Gurnee (Patients Seen; IP Delivered)
      • Gurnee, Illinois, Stany Zjednoczone, 60031
        • Medical Eye Services LTD (Ophthalmoscopy with OCT)
      • Lake Bluff, Illinois, Stany Zjednoczone, 60044
        • North Shore Endoscopy Center (Endoscopy)
      • Libertyville, Illinois, Stany Zjednoczone, 60048
        • Libertyville Imaging Center (Diagnostic Imaging)
      • Morton Grove, Illinois, Stany Zjednoczone, 60053
        • 3T Imaging of Morton Grove (Diagnostic Imaging)
    • Maryland
      • Columbia, Maryland, Stany Zjednoczone, 21045
        • Cascades Endoscopy Center
      • Columbia, Maryland, Stany Zjednoczone, 21044
        • Charter Radiology
      • Columbia, Maryland, Stany Zjednoczone, 21045
        • Gastro Center of Maryland, LLC
      • Hanover, Maryland, Stany Zjednoczone, 21076
        • Kaylani Eye Care ( Optical Coherence Tomography and Opthalmoscopy only)
      • Laurel, Maryland, Stany Zjednoczone, 20707
        • Lung Center (Pulmonary Function Test only)
    • Mississippi
      • Jackson, Mississippi, Stany Zjednoczone, 39216
        • Southern Therapy and Advanced Research, LLC
      • Jackson, Mississippi, Stany Zjednoczone, 39216
        • A Terrell Williams, MD, PLLC (OCT)
      • Jackson, Mississippi, Stany Zjednoczone, 39216
        • Jackson Pulmonary Associates (PFT)
      • Jackson, Mississippi, Stany Zjednoczone, 39216
        • St. Dominic Ambulatory Surgery Center (colonoscopy, Endoscopy)
    • Missouri
      • Creve Coeur, Missouri, Stany Zjednoczone, 63141
        • Barnes-Jewish West County Hospital (Additional Endoscopy Location)
      • St Louis, Missouri, Stany Zjednoczone, 63110
        • Barnes-Jewish Hospital
      • St Louis, Missouri, Stany Zjednoczone, 63110
        • Washington University School of Medicine
      • St Louis, Missouri, Stany Zjednoczone, 63108
        • Washington University School of Medicine
    • New Jersey
      • Freehold, New Jersey, Stany Zjednoczone, 07728
        • Allied Health Clinical Research Organization, LLC
      • Freehold, New Jersey, Stany Zjednoczone, 07728
        • Freehold Endoscopy Associates, LLC d/b/a Endoscopy Center of Monmouth County
      • Freehold, New Jersey, Stany Zjednoczone, 07728
        • Freehold Ophthalmology
      • Freehold, New Jersey, Stany Zjednoczone, 07728
        • Monmouth Ocean Pulmonary Medicine
      • Freehold, New Jersey, Stany Zjednoczone, 07728
        • Princeton Radiology
    • New York
      • New York, New York, Stany Zjednoczone, 10016
        • NYU Langone Health
      • New York, New York, Stany Zjednoczone, 10016
        • NYU Langone Inflammatory Bowel Disease Center
      • New York, New York, Stany Zjednoczone, 10016
        • NYU Langone Eye Center (Ophthalmology)
      • New York, New York, Stany Zjednoczone, 10016
        • NYU Langone Health - Ambulatory Care Center
      • New York, New York, Stany Zjednoczone, 10016
        • NYU Langone Health, Investigational Pharmacy, Perlmutter Cancer Center
      • New York, New York, Stany Zjednoczone, 10016
        • NYU Pulmonary and Critical Care Associates (Pulmonary)
    • North Carolina
      • Charlotte, North Carolina, Stany Zjednoczone, 28215
        • Carolinas Research Center
      • Charlotte, North Carolina, Stany Zjednoczone, 28204
        • Queen City Gastroenterology and Hepatology (Endoscopy)
      • Charlotte, North Carolina, Stany Zjednoczone, 28211
        • Greenman Eye Associates (OCT)
      • Charlotte, North Carolina, Stany Zjednoczone, 28273
        • Cornerstone Medical (Imaging & PFT)
    • Ohio
      • Chardon, Ohio, Stany Zjednoczone, 44024
        • Geauga Sleep Center(PFT only)
      • Cincinnati, Ohio, Stany Zjednoczone, 45219
        • UC Health Physicians Office
      • Cincinnati, Ohio, Stany Zjednoczone, 45229
        • UC Health (Pulmonary Function Testing)
      • Cincinnati, Ohio, Stany Zjednoczone, 45219
        • UC Health Hoxworth (OCT only)
      • Cincinnati, Ohio, Stany Zjednoczone, 45219
        • University of Cincinnati Medical Center (PFT and Endoscopy location)
      • Mentor, Ohio, Stany Zjednoczone, 44060
        • Great Lakes Gastroenterology Research, LLC
      • Mentor, Ohio, Stany Zjednoczone, 44060
        • The Endoscopy Center of Lake County
      • Mentor, Ohio, Stany Zjednoczone, 44060
        • Ophthalmic Physicians Incorporated (OCT Only)
      • Mentor, Ohio, Stany Zjednoczone, 44060
        • Vitreo Retinal Consultants(OCT only)
      • Willoughby, Ohio, Stany Zjednoczone, 44094
        • Lake Pulmonary Associates (PFT only)
      • Willoughby Hills, Ohio, Stany Zjednoczone, 44094
        • Retina Specialists of Ohio(OCT only)
    • Oklahoma
      • Norman, Oklahoma, Stany Zjednoczone, 73071
        • Norman Endoscopy Center
      • Norman, Oklahoma, Stany Zjednoczone, 73071
        • Physicians and Surgeons X-Ray
      • Oklahoma City, Oklahoma, Stany Zjednoczone, 73118
        • Central Sooner Research
      • Oklahoma City, Oklahoma, Stany Zjednoczone, 73102
        • Hightower Clinical
      • Oklahoma City, Oklahoma, Stany Zjednoczone, 73102
        • Saint Anthony Endoscopy Center
      • Oklahoma City, Oklahoma, Stany Zjednoczone, 73102
        • SSM Health, Saint Anthony Hospital
      • Oklahoma City, Oklahoma, Stany Zjednoczone, 73120
        • Johnston Opthalmology
    • Pennsylvania
      • Hershey, Pennsylvania, Stany Zjednoczone, 17033
        • Penn State Milton S. Hershey Medical Center
    • Texas
      • Austin, Texas, Stany Zjednoczone, 78705
        • Central Texas Clinical Research
      • Cypress, Texas, Stany Zjednoczone, 77429
        • Houston Pulmonary Sleep and Allergy Associates (PFT)
      • Houston, Texas, Stany Zjednoczone, 77030
        • The University of Texas Health Science Center at Houston
      • Houston, Texas, Stany Zjednoczone, 77030
        • Baylor St. Luke's Medical Center
      • Houston, Texas, Stany Zjednoczone, 77047
        • Pearland Surgery Center
      • Houston, Texas, Stany Zjednoczone, 77030
        • Alkek Eye Center Jamail Specialty Care Center (OCT)
      • Houston, Texas, Stany Zjednoczone, 77024
        • Houston Eye Associates (For Eye Examination)
      • Houston, Texas, Stany Zjednoczone, 77030
        • Baylor College of Medicine - Baylor St. Luke's Medical Center
      • Houston, Texas, Stany Zjednoczone, 77030
        • Baylor St. Luke's Medical Center - McNair Campus (pharmacy)
      • Houston, Texas, Stany Zjednoczone, 77030
        • Baylor St. Luke's Medical Center - McNair Campus
      • Houston, Texas, Stany Zjednoczone, 77030
        • Baylor St. Luke's Medical Center Endoscopy - McNair Campus
      • Houston, Texas, Stany Zjednoczone, 77030
        • Mann Eye Institute
      • Houston, Texas, Stany Zjednoczone, 77030
        • Memorial Hermann Hospital- TMC Investigational Drugs Services Pharmacy (Drug Storage)
      • Houston, Texas, Stany Zjednoczone, 77034
        • Bay Area Endoscopy Center, LLC
      • Houston, Texas, Stany Zjednoczone, 77055
        • Memorial Endoscopy Center (For Colonoscopy)
      • Houston, Texas, Stany Zjednoczone, 77065
        • Eye Specialists of Texas
      • Houston, Texas, Stany Zjednoczone, 77065
        • Northside Gastroenterology Associates PA
      • Houston, Texas, Stany Zjednoczone, 77079
        • Memorial Pulmonology(For PFT)
      • Houston, Texas, Stany Zjednoczone, 77204
        • Digestive Health Associates
      • Houston, Texas, Stany Zjednoczone, 77204
        • Memorial Hermann Memorial City Digestive Health Center (For Colonoscopy)
      • Pearland, Texas, Stany Zjednoczone, 77584
        • LinQ Research, LLC
      • Tyler, Texas, Stany Zjednoczone, 75701
        • Tyler Research Institute, LLC
      • Tyler, Texas, Stany Zjednoczone, 75701
        • UT Health East Texas Physicians (pulmonary functions only)
      • Tyler, Texas, Stany Zjednoczone, 75701
        • Christus Trinity Mother Frances Endoscopy Center (endoscopies only)
      • Tyler, Texas, Stany Zjednoczone, 75701
        • Heaton Eye Associates (OCT only)
      • Victoria, Texas, Stany Zjednoczone, 77904
        • Victoria Gastroenterology
      • Victoria, Texas, Stany Zjednoczone, 77904
        • Citizens Healthplex (for PFT only)
      • Victoria, Texas, Stany Zjednoczone, 77904
        • Surgery Center (For endoscopy only)
      • Victoria, Texas, Stany Zjednoczone, 77904
        • Victoria Eye Center (For OCT only)
      • Webster, Texas, Stany Zjednoczone, 77598
        • GI Alliance Webster
    • Virginia
      • Forest, Virginia, Stany Zjednoczone, 24551
        • Harman Eye Center (OCT only)
      • Lynchburg, Virginia, Stany Zjednoczone, 24502
        • Blue Ridge Medical Research
      • Lynchburg, Virginia, Stany Zjednoczone, 24501
        • Lynchburg Pulmonary Associates, Inc. (PFT only)
    • Washington
      • Issaquah, Washington, Stany Zjednoczone, 98029
        • Swedish Endoscopy Center - Issaquah
      • Seattle, Washington, Stany Zjednoczone, 98122
        • Swedish Medical Center
      • Seattle, Washington, Stany Zjednoczone, 98104
        • Swedish Gastroenterology
      • Seattle, Washington, Stany Zjednoczone, 98104
        • Pacific Northwest Retina
      • Seattle, Washington, Stany Zjednoczone, 98104
        • Richard Bensinger, MD
      • Seattle, Washington, Stany Zjednoczone, 98122
        • First Hill Endoscopy Center
      • Seattle, Washington, Stany Zjednoczone, 98122
        • Pulmonary Function Lab
    • Wisconsin
      • Milwaukee, Wisconsin, Stany Zjednoczone, 53226
        • Froedtert Memorial Lutheran Hospital
      • Bern, Szwajcaria, 3010
        • Inselspital Bern
      • Bern, Szwajcaria, 3012
        • OCT/Ophtalmoscopy: Berner Augenklinik am Lindenhofspital
      • Banská Bystrica, Słowacja, 975 17
        • Fakultna nemocnica s poliklinikou F.D.Roosevelta
      • Bardejov, Słowacja, 08501
        • ALIAN. s.r.o .. Ambulancia vnutorneho lekarstva
      • Košice, Słowacja, 040 13
        • ENDOMED, s.r.o. Gastroenterologicka ambulancia
      • Lipany, Słowacja, 082 71
        • Opthalmology outpatient clinic, MUDr. Michal Popovec, s.r.o.
      • Nitra, Słowacja, 949 01
        • KM Management spol.s.r.o. Gastroenterologicke a hepatologicke centrum
      • Prešov, Słowacja, 080 01
        • GASTRO LM s.r.o., Gastroenterologicka ambulancia
      • Prešov, Słowacja, 080 01
        • Pneumology: PULMO, s.r.o.
      • Ankara, Turcja (Türkiye), 06500
        • Gazi University Medical Faculty
      • Ankara, Turcja (Türkiye), 06100
        • Hacettepe University Medical Faculty
      • Ankara, Turcja (Türkiye), 06800
        • T.C. Saglik Bakanligi Ankara Sehir Hastanesi
      • Antalya, Turcja (Türkiye), 07100
        • Saglik Bilimleri Universitesi Antalya Egitim ve Arastirma Hastanesi
      • Izmir, Turcja (Türkiye), 35100
        • Ege Universitesi Tip Fakultesi Hastanesi
      • Kocaeli, Turcja (Türkiye), 41380
        • Kocaeli University Research and Training Hospital
      • Yenişehir, Turcja (Türkiye), 33343
        • Mersin University Faculty of Medicine
      • Kharkiv, Ukraina, 61124
        • Communal Non-commercial Enterprise City Clinical Hospital #13 of Kharkiv City Council
      • Kharkiv, Ukraina, 61024
        • LLC "EyeQClinic"
      • Kharkiv, Ukraina, 61022
        • Llc "Ldts Skaymed'
      • Kharkiv, Ukraina, 61037
        • Communal Non-commercial Enterprise Prof. O.O. Shalimov City Clinical Hospital #2 of Kharkiv
      • Kharkiv, Ukraina, 61045
        • Llc "Medical Center Oftalmika"
      • Kharkiv, Ukraina, 61103
        • Municipal Health Care "Kharkiv City Hospital Ambulance and Emergency Medical care
      • Kyiv, Ukraina, 01135
        • Medical Center of Limited Liability Company Harmoniia Krasy
      • Kyiv, Ukraina, 02091
        • Med Center 'Ok!Clinic+' of Comp with limited liability "Int Inst of Clin Research", Unit of Gastro
      • Kyiv, Ukraina, 04210
        • Private Enterprise "Clinic Medicom"
      • Lutsk, Ukraina, 43005
        • CE Volyn Reg Clinical Hospital ofVolyn Reg Council, Surgical (Endocrine and Abdominal Pathology)
      • Vinnytsia, Ukraina, 21000
        • Private Enterprise Diagnostic Center "Mediscan"
      • Vinnytsia, Ukraina, 21009
        • Medical Center of LLC Health Clinic, Medical Clinical Research Center, Unit of Gastroenterology,
      • Vinnytsia, Ukraina, 21018
        • CNE of M.I. Pyrohov Vinnytsia Regional Clinical Hospital of Vinnytsia Regional Council, Reg
      • Vinnytsia, Ukraina, 21029
        • Scientific and Research Institute of Invalid Rehabilitation (Educational, Scientific and Treatment
      • Budapest, Węgry, 1136
        • Pannonia Maganorvosi Centrum
      • Budapest, Węgry, 1033
        • Clinexpert Egeszsegugyi Szolgaltato es Kereskedelmi Kft. (abbreviated name: Clinexpert Kft.)
      • Budapest, Węgry, 1062
        • Ophthalmology procedures: Magyar Honvedseg Egeszsegugyi Kozpont
      • Budapest, Węgry, 1062
        • Pulmonary procedures: Vasutegeszsegugyi Nonprofit Kozhasznu K ft.
      • Budapest, Węgry, 1134
        • Ophthalmology, OCT: Medicover Zrt.
      • Budapest, Węgry, 1139
        • Chest X-ray: XIII. keruleti Egeszsegugyi Szolgalat Kozhasznu Nonprofit Kft.
      • Békéscsaba, Węgry, 5600
        • Bekes Megyei Kozponti Korhaz Dr. Rethy Pal Tagkorhaz, 4. Belgyogyaszat es 2. Gasztroenterologia
    • Heves County
      • Gyöngyös, Heves County, Węgry, 3200
        • Bugat Pal Korhaz, Gasztroenterologia
    • Komárom-Esztergom
      • Tatabánya, Komárom-Esztergom, Węgry, 2800
        • Szent Borbala Korhaz
      • Tatabánya, Komárom-Esztergom, Węgry, 2800
        • DLCO and ophthalmology tests: Szent Borbala Korhaz
      • Catania, Włochy, 829-95126
        • Azienda Ospedaliera Ospedale Cannizzaro
      • Catanzaro, Włochy, 88100
        • A.O. Mater Domini, U.O. Fisiopatologia Apparato Digerente Campus Universitario "Salvatore Venuta"
      • Catanzaro, Włochy, 88100
        • A.O. Mater Domini, U.O. Fisiopatologia Apparato Digerente
      • Catanzaro, Włochy, 88100
        • CAMPUS GERMANETO Magazzino farmaci e dispositivi medici, uffici
      • Pavia, Włochy, 27100
        • Fondazione IRCCS Policlinico San Matteo - Centro per lo Studio e la Cura delle Amiloidosi Sistemiche
      • Rome, Włochy, 00189
        • PFT address: Azienda Ospedaliero-Universitaria Sant' Andrea UOC Pneumologia
      • Verona, Włochy, 37024
        • IRCCS Ospedale Sacro Cuore Don Calabria
      • Verona, Włochy, 37134
        • OCT/PFT/Endoscopy address: CRC - Cenro Ricerche Cliniche di Verona
    • Foggia
      • San Giovanni Rotondo, Foggia, Włochy, 71013
        • IRCCS Ospedale Casa Sollievo della Sofferenza
      • San Giovanni Rotondo, Foggia, Włochy, 71013
        • OCT/ PFT/ Endoscopy address: IRCCS Ospedale Casa Sollievo della Sofferenza
    • MI
      • Milan, MI, Włochy, 20132
        • Ospedale San Raffaele
    • Milan
      • Garbagnate Milanese, Milan, Włochy, 20024
        • ASST Rhodense - Pneumology Unit
      • Milan, Milan, Włochy, 20017 Rho
        • ASST Rhodense, U.O.C. Gastroenterologia ed Endoscopia Digestiva
      • Rho, Milan, Włochy, 20017
        • ASST Rhodense - Ophthalmology Unit
    • Milano
      • Rozzano, Milano, Włochy, 20089
        • Irccs Humanitas Research Hospital
    • Verona
      • Negrar, Verona, Włochy, 37024
        • OCT/ PFT/ Endoscopy address: IRCCS Ospedale Sacro Cuore Don Calabria
      • Liverpool, Zjednoczone Królestwo, L7 8XP
        • Royal Liverpool University Hospital
      • London, Zjednoczone Królestwo, SE1 9RT
        • Guys & St Thomas Hospital
      • Norwich, Zjednoczone Królestwo, NR4 7UQ
        • Quadram Institute Clinical Research Facility

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

18 lat do 80 lat (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Opis

Kryteria kwalifikowalności mające zastosowanie do wszystkich badań cząstkowych:

Kryteria przyjęcia:

  • Mężczyźni lub kobiety w wieku od 18 do 80 lat,
  • Zdolność do wyrażenia pisemnej świadomej zgody lub zgody oraz przestrzegania harmonogramu ocen protokołów
  • Zdiagnozowana choroba Leśniowskiego-Crohna (CD) ≥ 3 miesiące
  • Mieć umiarkowanie lub silnie aktywną CD podczas badania przesiewowego
  • Wykazano niewystarczającą odpowiedź (tj. pierwotny brak odpowiedzi), utratę odpowiedzi lub nietolerancję na ≥ 1 z następujących terapii stosowanych w leczeniu CD:

    1. Doustne kortykosteroidy (np. prednizon lub jego odpowiednik, budezonid)
    2. Leki immunosupresyjne (np. azatiopryna [AZA], 6-merkaptopuryna [6-MP] lub metotreksat [MTX])
    3. Antagoniści czynnika martwicy nowotworów alfa (TNFα) (np. infliksymab, adalimumab, certolizumab pegol lub leki biopodobne)
    4. Antagonista receptora integryny (np. wedolizumab)
    5. Antagoniści interleukiny -12/-23 (np. ustekinumab)
  • Kobiety w wieku rozrodczym nie mogą być w ciąży
  • Kobiety w wieku rozrodczym i mężczyźni muszą stosować antykoncepcję

Kryteria wyłączenia:

  • Historia niewystarczającej odpowiedzi (tj. pierwotnego braku odpowiedzi) na środki z ≥ 2 klas leków biologicznych sprzedawanych do leczenia CD (tj. antagoniści TNFα, antagoniści interleukiny 12/23 i antagoniści receptora integryny).
  • Masz wrzodziejące zapalenie jelita grubego, nieokreślone zapalenie jelita grubego, mikroskopowe zapalenie jelita grubego, niedokrwienne zapalenie jelita grubego, zapalenie jelita grubego popromienne, zapalenie jelita grubego związane z chorobą uchyłkową jelita grubego, toksyczne rozszerzenie okrężnicy lub aktywne zakaźne zapalenie jelita grubego lub pozytywny wynik testu na obecność toksyny Clostridioides difficile podczas badania przesiewowego.
  • Mają czynnościowy lub pooperacyjny zespół krótkiego jelita lub jakiekolwiek powiązane powikłania, które mogą wymagać operacji lub zakłócać ocenę skuteczności
  • Przeszli leczenie chirurgiczne ropni w obrębie jamy brzusznej ≤ 8 tygodni przed randomizacją lub leczenie chirurgiczne ropni okołoodbytniczych ≤ 4 tygodnie przed randomizacją.
  • Miał resekcję jelita ≤ 24 tygodnie przed randomizacją lub inne operacje w obrębie jamy brzusznej ≤ 12 tygodni przed randomizacją.
  • Mieć ileostomię lub kolostomię.

Kryteria włączenia do badania częściowego 3:

- Uczestnicy, którzy przystąpili do przedłużonego okresu wprowadzającego w badaniu dodatkowym 1 i badaniu dodatkowym 2, muszą ukończyć rozszerzoną wizytę wprowadzającą w 6. tygodniu

Kryteria włączenia do badania częściowego 4:

- Uczestnik musi odbyć wizytę w 52. tygodniu w ramach badania podrzędnego 3 lub wizytę w 66. tygodniu w ramach badania podrzędnego A

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Przydział: Randomizowane
  • Model interwencyjny: Przydział równoległy
  • Maskowanie: Podwójnie

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Komparator placebo: Placebo
Tabletka etrasimodu odpowiadająca placebo, przyjmowana doustnie, raz dziennie.
Eksperymentalny: Etrasimod Dawka A
Dawka A przyjmowana doustnie, raz dziennie.
Inne nazwy:
  • APD334
Dawka B przyjmowana doustnie, raz dziennie.
Inne nazwy:
  • APD334
Eksperymentalny: Etrasimod Dawka B
Dawka A przyjmowana doustnie, raz dziennie.
Inne nazwy:
  • APD334
Dawka B przyjmowana doustnie, raz dziennie.
Inne nazwy:
  • APD334

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Percentage of Participants With Endoscopic Response by Simple Endoscopic Score in Crohn's Disease (SES-CD) at Week 14: SSA
Ramy czasowe: Week 14 of SSA
Endoscopic response: SES-CD score <=4 and at least 2-point reduction from baseline with no subscore >1 or >=50% decrease from study baseline in SES-CD. SES-CD consisted of a composite score based on 4 components: size of ulcers, ulcerated surface, affected surface and presence of narrowing assessed in 5 bowel segments: ileum; right; transverse; left colon and rectum. Size of ulcers score: 0= none, 1= aphthous ulcers, 2= large ulcers and 3= very large ulcers. Ulcerated surface score: 0= none, 1= <10%, 2= 10% - 30% and 3= >30%. Affected surface score: 0= unaffected segment, 1= <50%, 2= 50% - 75%, and 3= >75%. Presence of narrowing score: 0= none, 1= single, can be passed, 2= multiple, can be passed, 3= cannot be passed. Total SES-CD= sum of each component score for all 5 bowel segments and ranged from 0 (no disease) to 60 (severe disease), higher score indicated more severe disease.
Week 14 of SSA
Percentage of Participants With Endoscopic Response by SES-CD at Week 14: SS1
Ramy czasowe: Week 14 of SS1
Endoscopic response: SES-CD score <=4 and at least 2-point reduction from baseline with no subscore >1 or >=50% decrease from study baseline in SES-CD. SES-CD consisted of composite score based on 4 components: size of ulcers, ulcerated surface, affected surface and presence of narrowing assessed in 5 bowel segments: ileum; right; transverse; left colon and rectum. Size of ulcers score: 0= none, 1= aphthous ulcers, 2= large ulcers and 3= very large ulcers. Ulcerated surface score: 0= none, 1= <10%, 2= 10% - 30% and 3= >30%. Affected surface score: 0= unaffected segment, 1= <50%, 2= 50% - 75%, and 3= >75%. Presence of narrowing score: 0= none, 1= single, can be passed, 2= multiple can be passed, 3= cannot be passed. Total SES CD= sum of each component score for all 5 bowel segments and ranged from 0 (no disease)-60 (severe disease), higher score indicated more severe disease. Multiple imputation (MI) method used; percentage calculated based on average response rate from MI datasets.
Week 14 of SS1
Percentage of Participants With Clinical Remission by CDAI at Week 52: SS3 Responder Cohort
Ramy czasowe: Week 52 of study
Clinical remission was considered as CDAI score <150. CDAI was a composite index consisting of a weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); hematocrit (HCT): 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score was calculated as the sum of variable scores*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores indicated more severe disease.
Week 52 of study
Percentage of Participants With Clinical Remission by CDAI at Week 52: SS3 Non-Responder Cohort
Ramy czasowe: Week 52 of study
Clinical remission was considered as CDAI score <150. CDAI was a composite index consisting of a weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); HCT: 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score was calculated as the sum of variable scores*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores indicated more severe disease.
Week 52 of study
Percentage of Participants With Endoscopic Response by SES-CD at Week 52: SS3 Responder Cohort
Ramy czasowe: Week 52 of study
Endoscopic response: SES-CD score <=4 and at least 2-point reduction from baseline with no subscore >1 or >=50% decrease from parent study (SS1) baseline in SES-CD. SES-CD consisted of composite score based on size of ulcers, ulcerated surface, affected surface and presence of narrowing assessed in 5 segments: ileum; right; transverse; left colon; rectum. Size of ulcers score: 0=none, 1=aphthous ulcers,2=large ulcers,3=very large ulcers. Ulcerated surface score: 0= none, 1= <10%, 2= 10% - 30%, 3= >30%. Affected surface score: 0= unaffected segment, 1= <50%,2= 50%-75%,3= >75%. Presence of narrowing score: 0=none,1=single, can be passed, 2=multiple, can be passed,3=cannot be passed. Total SES CD=sum of each domain score for all 5 bowel segments and ranged from 0 (no disease) to 60 (severe disease), higher score= more severe disease.
Week 52 of study
Percentage of Participants With Endoscopic Response by SES-CD at Week 52: SS3 Non-Responder Cohort
Ramy czasowe: Week 52 of study
Endoscopic response: SES-CD score <=4 and at least 2-point reduction from baseline with no subscore >1 or >=50% decrease from parent study (SS1) baseline in SES-CD. SES-CD consisted of composite score based on size of ulcers, ulcerated surface, affected surface and presence of narrowing assessed in 5 segments: ileum; right, transverse; left colon; rectum. Size of ulcers score: 0=none, 1=aphthous ulcers,2=large ulcers,3=very large ulcers. Ulcerated surface score: 0= none, 1= <10%, 2= 10% - 30%, 3= >30%. Affected surface score: 0= unaffected segment, 1= <50%,2= 50%-75%,3= >75%. Presence of narrowing score: 0=none,1=single, can be passed, 2=multiple, can be passed,3=cannot be passed. Total SES CD=sum of each domain score for all 5 bowel segments and ranged from 0 (no disease) to 60 (severe disease), higher score= more severe disease.
Week 52 of study

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Percentage of Participants With Clinical Remission by CDAI at Week 14: SSA
Ramy czasowe: Week 14 of SSA
Clinical remission was considered as CDAI score <150. CDAI was a composite index consisting of a weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); HCT: 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score was calculated as the sum of variable scores*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores indicated more severe disease.
Week 14 of SSA
Change From Baseline in SES-CD Score at Week 14: SSA
Ramy czasowe: Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
SES-CD consisted of a composite score based on 4 components: size of ulcers, ulcerated surface, affected surface and presence of narrowing assessed in 5 bowel segments: ileum; right; transverse; left colon and rectum. Size of ulcers score: 0= none, 1= aphthous ulcers, 2= large ulcers and 3= very large ulcers. Ulcerated surface score: 0= none, 1= <10%, 2= 10% - 30% and 3= >30%. Affected surface score: 0= unaffected segment, 1= <50%, 2= 50% - 75%, and 3= >75%. Presence of narrowing score: 0= none, 1= single, can be passed, 2= multiple, can be passed, 3= cannot be passed. Total SES-CD= sum of each component score for all 5 bowel segments and ranged from 0 (no disease) to 60 (severe disease), higher score indicated more severe disease.
Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
Change From Baseline in CDAI Score at Week 14: SSA
Ramy czasowe: Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
CDAI was a composite index consisting of a weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); HCT: 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score was calculated as the sum of variable scores*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores indicated more severe disease.
Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
Plasma Concentration of Etrasimod at 4 Hours Post-dose: SSA
Ramy czasowe: 4 hours post-dose on Day 1
The plasma concentration of etrasimod at 4 hours post-dose has been reported in this outcome measure.
4 hours post-dose on Day 1
Steady State Trough Concentration (Ctrough,ss) of Etrasimod From Week 2 to Week 14: SSA
Ramy czasowe: From Week 2 to Week 14
The average steady-state Ctrough for Week 2 through 14 was calculated based on individual Ctrough data from Week 2, Week 6 and Week 14.
From Week 2 to Week 14
Change From Baseline in Absolute Lymphocyte Count (ALC) at Week 14 in Induction Period: SSA
Ramy czasowe: Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
Percent Change From Baseline in ALC at Week 14 in Induction Period: SSA
Ramy czasowe: Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
Change From Baseline in ALC at Week 66 in Extension Period: SSA
Ramy czasowe: Baseline (last measurement taken prior to the first dose of study treatment) and Week 66 of SSA
Baseline (last measurement taken prior to the first dose of study treatment) and Week 66 of SSA
Percent Change From Baseline in ALC at Week 66 in Extension Period: SSA
Ramy czasowe: Baseline (last measurement taken prior to the first dose of study treatment) and Week 66 of SSA
Baseline (last measurement taken prior to the first dose of study treatment) and Week 66 of SSA
Change From Baseline in Fecal Calprotectin (FCP) Concentration at Week 14 in Induction Period: SSA
Ramy czasowe: Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
Percent Change From Baseline in FCP Concentration at Week 14 in Induction Period: SSA
Ramy czasowe: Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
Change From Baseline in FCP Concentration at Week 66 in Extension Period: SSA
Ramy czasowe: Baseline (last measurement taken prior to the first dose of study treatment) and Week 66 of SSA
Baseline (last measurement taken prior to the first dose of study treatment) and Week 66 of SSA
Percent Change From Baseline in FCP Concentration at Week 66 in Extension Period: SSA
Ramy czasowe: Baseline (last measurement taken prior to the first dose of study treatment) and Week 66 of SSA
Baseline (last measurement taken prior to the first dose of study treatment) and Week 66 of SSA
Change From Baseline in C-Reactive Protein (CRP) at Week 14 in Induction Period: SSA
Ramy czasowe: Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
Percent Change From Baseline in CRP at Week 14 in Induction Period: SSA
Ramy czasowe: Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
Change From Baseline in CRP at Week 66 in Extension Period: SSA
Ramy czasowe: Baseline (last measurement taken prior to the first dose of study treatment) and Week 66 of SSA
Baseline (last measurement taken prior to the first dose of study treatment) and Week 66 of SSA
Percent Change From Baseline in CRP at Week 66 in Extension Period: SSA
Ramy czasowe: Baseline (last measurement taken prior to the first dose of study treatment) and Week 66 of SSA
Baseline (last measurement taken prior to the first dose of study treatment) and Week 66 of SSA
Percentage of Participants With Clinical Remission by CDAI at Week 14: SS1
Ramy czasowe: Week 14 of SS1
Clinical remission was considered as CDAI score <150. CDAI was a composite index consisting of a weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); HCT: 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score was calculated as the sum of variable scores*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores indicated more severe disease. MI method was used; percentage was calculated based on average response rate from MI datasets.
Week 14 of SS1
Percentage of Participants With Clinical Remission by Patient Reported Outcomes 2 (PRO2) at Week 14: SS1
Ramy czasowe: Week 14 of SS1
Clinical remission was defined as PRO2 score <8. The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain. MI method was used; percentage was calculated based on average response rate from MI datasets.
Week 14 of SS1
Percentage of Participants With Clinical Remission by CDAI at Week 52 Among Participants With Clinical Remission by CDAI at SS3 Baseline: SS3 Responder Cohort
Ramy czasowe: Week 52 of study
Clinical remission was CDAI score <150. CDAI was a composite index consisting of weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of abdominal mass (0 as none, 2 as questionable, 5 as definite); HCT: 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score: sum of variable scores*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores= more severe disease. SS3 Baseline was last non-missing measurement taken prior to date of FMD of SS3.
Week 52 of study
Percentage of Participants With Clinical Remission by CDAI at Week 52 Among Participants With Clinical Remission by CDAI at SS3 Baseline: SS3 Non-Responder Cohort
Ramy czasowe: Week 52 of study
Clinical remission was CDAI score <150. CDAI was a composite index consisting of weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of abdominal mass (0 as none, 2 as questionable, 5 as definite); HCT: 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score: sum of variable scores*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores= more severe disease. SS3 Baseline was last non-missing measurement taken prior to date of FMD of SS3.
Week 52 of study
Percentage of Participants With Endoscopic Response at Week 52 Among Participants With Endoscopic Response at SS3 Baseline: SS3 Responder Cohort
Ramy czasowe: Week 52 of study
Endoscopic response: SES-CD score <=4 and at least 2-point reduction from baseline with no subscore >1 or >=50% decrease from parent study (SS1) baseline in SES-CD. SES-CD= composite score based on 4 components: size of ulcers, ulcerated surface, affected surface, presence of narrowing in 5 segments: ileum; right; transverse; left colon; rectum. Size of ulcers score: 0=none,1= aphthous ulcers, 2= large ulcers, 3= very large ulcers. Ulcerated surface score: 0= none,1= <10%, 2= 10%-30%, 3= >30%. Affected surface score: 0= unaffected segment, 1= <50%, 2= 50%-75%,3= >75%. Presence of narrowing score: 0= none,1= single, can be passed, 2= multiple can be passed, 3= can't be passed. Total SES CD=sum of component scores for 5 bowel segments and ranged from 0 (no disease) - 60 (severe disease), higher score indicated more severe disease. SS3 Baseline was last non-missing measurement taken prior to FMD date.
Week 52 of study
Percentage of Participants With Endoscopic Response at Week 52 Among Participants With Endoscopic Response at SS3 Baseline: SS3 Non-Responder Cohort
Ramy czasowe: Week 52 of study
Endoscopic response: SES-CD score <=4 and at least 2-point reduction from baseline with no subscore >1 or >=50% decrease from parent study (SS1) baseline in SES-CD. SES-CD= composite score based on 4 components: size of ulcers, ulcerated surface, affected surface, presence of narrowing in 5 segments: ileum; right; transverse; left colon; rectum. Size of ulcers score: 0=none,1= aphthous ulcers, 2= large ulcers, 3= very large ulcers. Ulcerated surface score: 0= none,1= <10%, 2= 10%-30%, 3= >30%. Affected surface score: 0= unaffected segment, 1= <50%, 2= 50%-75%,3= >75%. Presence of narrowing score: 0= none,1= single, can be passed, 2= multiple can be passed, 3= can't be passed. Total SES CD=sum of component scores for 5 bowel segments and ranged from 0 (no disease) - 60 (severe disease), higher score indicated more severe disease. SS3 Baseline was last non-missing measurement taken prior to FMD date.
Week 52 of study
Percentage of Participants With Corticosteroid-Free Clinical Remission by CDAI at Week 52 Among Participants Receiving Corticosteroids at SS3 Baseline: SS3 Responder Cohort
Ramy czasowe: Week 52 of study
Corticosteroid-free remission: CDAI score <150 without receiving corticosteroids for >=8 weeks prior to Week 52 (for participants receiving corticosteroids at baseline). CDAI: composite index consisting of weighted scoring of 8 disease activity variables: number of liquid stools; extent of abdominal pain from 0 (none)-3 (severe); general well-being from 0 (generally well)-4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of abdominal mass (0=none, 2=questionable, 5=definite); HCT 47 in men and 42 in women; percentage deviation from standard weight, lower bound -10. Total CDAI score=sum of variable scores*weighting factor and was from 0 (no disease)-600 (severe disease), higher score indicated more severe disease. SS3 Baseline was last non-missing measurement taken prior to date of FMD of SS3.
Week 52 of study
Percentage of Participants With Corticosteroid-Free Clinical Remission by CDAI at Week 52 Among Participants Receiving Corticosteroids at SS3 Baseline: SS3 Non-Responder Cohort
Ramy czasowe: Week 52 of study
Corticosteroid-free remission: CDAI score <150 without receiving corticosteroids for >=8 weeks prior to Week 52 (for participants receiving corticosteroids at baseline). CDAI: composite index consisting of weighted scoring of 8 disease activity variables: number of liquid stools; extent of abdominal pain from 0 (none)-3 (severe); general well-being from 0 (generally well)-4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of abdominal mass (0=none, 2=questionable, 5=definite); HCT 47 in men and 42 in women; percentage deviation from standard weight, lower bound -10. Total CDAI score=sum of variable scores*weighting factor and was from 0 (no disease)-600 (severe disease), higher score indicated more severe disease. SS3 Baseline was last non-missing measurement taken prior to date of FMD of SS3.
Week 52 of study
Percentage of Participants With Endoscopic Remission at Week 52: SS3 Responder Cohort
Ramy czasowe: Week 52 of study
Endoscopic remission: SES-CD score <=4 and at least 2-point reduction from baseline with no sub-score >1. SES-CD consisted of a composite score based on 4 components: size of ulcers, ulcerated surface, affected surface and presence of narrowing assessed in 5 segments: ileum; right; transverse; left colon and rectum. Size of ulcers score: 0=none, 1=aphthous ulcers, 2=large ulcers and 3=very large ulcers. Ulcerated surface score: 0= none, 1= <10%, 2= 10% - 30% and 3= >30%. Affected surface score: 0= unaffected segment, 1= <50%, 2= 50% - 75%, and 3= >75%. Presence of narrowing score: 0=none, 1= single, can be passed, 2=multiple, can be passed, 3= cannot be passed. Total SES CD=sum of each component score for all 5 bowel segments and ranged from 0 (no disease)-60 (severe disease), higher score indicated more severe disease.
Week 52 of study
Percentage of Participants With Endoscopic Remission at Week 52: SS3 Non-Responder Cohort
Ramy czasowe: Week 52 of study
Endoscopic remission: SES-CD score <=4 and at least 2-point reduction from baseline with no sub-score >1. SES-CD consisted of a composite score based on 4 components: size of ulcers, ulcerated surface, affected surface and presence of narrowing assessed in 5 segments: ileum; right; transverse; left colon and rectum. Size of ulcers score: 0=none, 1=aphthous ulcers, 2=large ulcers and 3=very large ulcers. Ulcerated surface score: 0= none, 1= <10%, 2= 10% - 30% and 3= >30%. Affected surface score: 0= unaffected segment, 1= <50%, 2= 50% - 75%, and 3= >75%. Presence of narrowing score: 0=none, 1= single, can be passed, 2=multiple, can be passed, 3= cannot be passed. Total SES CD=sum of each component score for all 5 bowel segments and ranged from 0 (no disease)-60 (severe disease), higher score indicated more severe disease.
Week 52 of study
Percentage of Participants With Clinical Remission by PRO2 at Week 52: SS3 Responder Cohort
Ramy czasowe: Week 52 of study
Clinical remission was defined as PRO2 score <8. The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain.
Week 52 of study
Percentage of Participants With Clinical Remission by PRO2 at Week 52: SS3 Non-Responder Cohort
Ramy czasowe: Week 52 of study
Clinical remission was defined as PRO2 score <8. The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain.
Week 52 of study
Percentage of Participants With Clinical Response or Endoscopic Response at Week 52: SS3 Responder Cohort
Ramy czasowe: Week 52 of study
Clinical response: clinical remission CDAI or >=100-point decrease from baseline in CDAI score where, clinical remission CDAI=CDAI <150. CDAI: composite index consisting of weighted scoring of 8 disease activity variables. Total CDAI: sum of variable scores*weighting factor and ranged from 0 (no disease) - 600 (severe disease), higher scores indicated more severe disease. Endoscopic response: SES-CD score <=4 and at least 2-point reduction from baseline with no subscore >1 or >=50% decrease from baseline in SES-CD. SES-CD comprised of 4 components assessed for 5 bowel segments. Each component score ranged from 0-3, higher scores indicated more severe condition. Total SES CD: sum of each component score of 5 bowel segments and ranged from 0 (no D) - 60 (severe disease), higher score indicated more severe disease. Percentage of participants with clinical response or endoscopic response at Week 52 is reported.
Week 52 of study
Percentage of Participants With Clinical Response or Endoscopic Response at Week 52: SS3 Non-Responder Cohort
Ramy czasowe: Week 52 of study
Clinical response: clinical remission CDAI or >=100-point decrease from baseline in CDAI score where, clinical remission CDAI=CDAI <150. CDAI: composite index consisting of weighted scoring of 8 disease activity variables. Total CDAI: sum of variable scores*weighting factor and ranged from 0 (no disease) - 600 (severe disease), higher scores indicated more severe disease. Endoscopic response: SES-CD score <=4 and at least 2-point reduction from baseline with no subscore >1 or >=50% decrease from baseline in SES-CD. SES-CD comprised of 4 components assessed for 5 bowel segments. Each component score ranged from 0-3, higher scores indicated more severe condition. Total SES CD: sum of each component score of 5 bowel segments and ranged from 0 (no D) - 60 (severe disease), higher score indicated more severe disease. Percentage of participants with clinical response or endoscopic response at Week 52 is reported.
Week 52 of study
Change From Baseline in CDAI Score at Weeks 20, 28, 36, 44 and 52: SS3 Responder Cohort
Ramy czasowe: Baseline, study Weeks 20, 28, 36, 44, 52
CDAI was a composite index consisting of a weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); HCT 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score was calculated as the sum of variable scores*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores indicated more severe disease. SS3 Baseline was last non-missing measurement taken prior to date of FMD of SS3.
Baseline, study Weeks 20, 28, 36, 44, 52
Change From Baseline in CDAI Score at Weeks 20, 28, 36, 44 and 52: SS3 Non-Responder Cohort
Ramy czasowe: Baseline, study Weeks 20, 28, 36, 44, 52
CDAI was a composite index consisting of a weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); HCT 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score was calculated as the sum of variable scores*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores indicated more severe disease. SS3 Baseline was last non-missing measurement taken prior to date of FMD of SS3.
Baseline, study Weeks 20, 28, 36, 44, 52
Percentage of Participants With Clinical Response by CDAI at Week 52 Among Participants With Clinical Response by CDAI at SS3 Baseline: SS3 Responder Cohort
Ramy czasowe: Week 52 of study
Clinical Response was clinical remission by CDAI or >=100-point decrease from baseline in CDAI score where, clinical remission CDAI= CDAI <150. CDAI: composite index consisting of weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none)-3 (severe); general well-being rating assessed from 0 (generally well) - 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide/opiates for diarrhea; presence of an abdominal mass (0=none, 2=questionable, 5=definite); HCT 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score= sum of variable scores*weighting factor and ranged from 0 (no disease) - 600 (severe disease), where higher scores indicated more severe disease. SS3 Baseline= last non-missing measurement taken prior to date of FMD of SS3.
Week 52 of study
Percentage of Participants With Clinical Response by CDAI at Week 52 Among Participants With Clinical Response by CDAI at SS3 Baseline: SS3 Non-Responder Cohort
Ramy czasowe: Week 52 of study
Clinical Response was clinical remission by CDAI or >=100-point decrease from baseline in CDAI score where, clinical remission CDAI= CDAI <150. CDAI: composite index consisting of weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none)-3 (severe); general well-being rating assessed from 0 (generally well) - 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide/opiates for diarrhea; presence of an abdominal mass (0=none, 2=questionable, 5=definite); HCT 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score= sum of variable scores*weighting factor and ranged from 0 (no disease) - 600 (severe disease), where higher scores indicated more severe disease. SS3 Baseline= last non-missing measurement taken prior to date of FMD of SS3.
Week 52 of study
Change From Baseline in Crohn's Disease Patient-Reported Outcomes (CD-PRO) Module Scores at Weeks 28 and 52: SS3 Responder Cohort
Ramy czasowe: Baseline, study Weeks 28 and 52
The CD-PRO was a validated instrument designed to assess the signs, symptoms, and impact of CD through 6 modules: Systemic Symptoms, Coping Strategies, Daily Life Impact, Emotional Impact, Bowel Signs and Symptoms and Functional Symptoms. Each module ranged from 0 to 16, where higher scores indicated more severe disease. SS3 Baseline was defined as last non-missing measurement taken prior to date of FMD of SS3.
Baseline, study Weeks 28 and 52
Change From Baseline in Crohn's Disease Patient-Reported Outcomes (CD-PRO) Module Scores at Weeks 28 and 52: SS3 Non-Responder Cohort
Ramy czasowe: Baseline, study Weeks 28 and 52
The CD-PRO was a validated instrument designed to assess the signs, symptoms, and impact of CD through 6 modules: Systemic Symptoms, Coping Strategies, Daily Life Impact, Emotional Impact, Bowel Signs and Symptoms and Functional Symptoms. Each module ranged from 0 to 16, where higher scores indicated more severe disease. SS3 Baseline was defined as last non-missing measurement taken prior to date of FMD of SS3.
Baseline, study Weeks 28 and 52
Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) at Weeks 28 and 52: SS3 Responder Cohort
Ramy czasowe: Baseline, study Weeks 28 and 52
The IBDQ was a validated 32 item questionnaire used to assess health related quality of life in participants with IBD. Response to each of the questions ranged from 1 to 7 where higher scores indicated better quality of life. The total IBDQ scores were calculated as sum of individual item scores and ranged from 32 (very poor health-related quality of life) to 224 (perfect health-related quality of life) where higher scores indicated better quality of life. SS3 Baseline was defined as last non-missing measurement taken prior to date of FMD of SS3.
Baseline, study Weeks 28 and 52
Change From Baseline in IBDQ at Weeks 28 and 52: SS3 Non-Responder Cohort
Ramy czasowe: Baseline, study Weeks 28 and 52
The IBDQ was a validated 32 item questionnaire used to assess health related quality of life in participants with IBD. Response to each of the questions ranged from 1 to 7 where higher scores indicated better quality of life. The total IBDQ scores were calculated as sum of individual item scores and ranged from 32 (very poor health-related quality of life) to 224 (perfect health-related quality of life) where higher scores indicated better quality of life. SS3 Baseline was defined as last non-missing measurement taken prior to date of FMD of SS3.
Baseline, study Weeks 28 and 52
Change From Baseline in Medical Outcomes Study 36-Item Short Form Health Survey (SF-36) at Weeks 28 and 52: SS3 Responder Cohort
Ramy czasowe: Baseline, study Weeks 28 and 52
The SF-36 was a health-related survey that assessed participant's health status and consisted of 36 questions measuring 8 health domains: physical functioning, bodily pain, role limitations due to physical problems, role limitations due to emotional problems, general health perceptions, mental health, social function and vitality. The 8 domains are combined to form 2 component scores mental (MCS) and physical (PCS). MCS consisted of social functioning, vitality, mental health, and role-emotional scales. PCS consisted of physical functioning, bodily pain, role-physical, and general health scales. Each domain was scored by summing the individual items and transforming the total SF-36 scores into a 0 to 100 scale with higher scores indicating better health status. SS3 Baseline= last non-missing measurement taken prior to date of FMD of SS3.
Baseline, study Weeks 28 and 52
Change From Baseline in SF-36 at Weeks 28 and 52: SS3 Non-Responder Cohort
Ramy czasowe: Baseline, study Weeks 28 and 52
The SF-36 was a health-related survey that assessed participant's health status and consisted of 36 questions measuring 8 health domains: physical functioning, bodily pain, role limitations due to physical problems, role limitations due to emotional problems, general health perceptions, mental health, social function and vitality. The 8 domains are combined to form 2 component scores MCS and PCS. MCS consisted of social functioning, vitality, mental health, and role-emotional scales. PCS consisted of physical functioning, bodily pain, role-physical, and general health scales. Each domain was scored by summing the individual items and transforming the total SF-36 scores into a 0 to 100 scale with higher scores indicating better health status. SS3 Baseline= last non-missing measurement taken prior to date of FMD of SS3.
Baseline, study Weeks 28 and 52
Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) at Weeks 28 and 52: SS3 Responder Cohort
Ramy czasowe: Baseline, study Weeks 28 and 52
The FACIT-F was a participant completed questionnaire consisting of 13 items that assess fatigue. Participants responded to each item on a 5-point scale based on their experience of fatigue during the past 7 days (0 = not at all; 1 = a little bit; 2 =somewhat; 3 = quite a bit; 4 = very much). Instrument scoring yielded a total FACIT-F score range from 0 to 52 (negatively worded items were reversed during analysis), with higher scores representing better participant status (less fatigue). SS3 Baseline= last non-missing measurement taken prior to date of FMD of SS3.
Baseline, study Weeks 28 and 52
Change From Baseline in FACIT-F at Weeks 28 and 52: SS3 Non-Responder Cohort
Ramy czasowe: Baseline, study Weeks 28 and 52
The FACIT-F was a participant completed questionnaire consisting of 13 items that assess fatigue. Participants responded to each item on a 5-point scale based on their experience of fatigue during the past 7 days (0 = not at all; 1 = a little bit; 2 =somewhat; 3 = quite a bit; 4 = very much). Instrument scoring yielded a total FACIT-F score range from 0 to 52 (negatively worded items were reversed during analysis), with higher scores representing better participant status (less fatigue). SS3 Baseline= last non-missing measurement taken prior to date of FMD of SS3.
Baseline, study Weeks 28 and 52
Percentage of Participants With Clinical Remission by PRO2 at Week 52 Among Participants With Clinical Remission by PRO2 at SS3 Baseline: SS3 Responder Cohort
Ramy czasowe: Week 52 of study
Clinical remission was defined as PRO2 score <8. The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain. SS3 Baseline was defined as last non-missing measurement taken prior to date of FMD of SS3.
Week 52 of study
Percentage of Participants With Clinical Remission by PRO2 at Week 52 Among Participants With Clinical Remission by PRO2 at Study Entry: SS3 Non-Responder Cohort
Ramy czasowe: Week 52 of study
Clinical remission was defined as PRO2 score <8. The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain. SS3 Baseline was defined as last non-missing measurement taken prior to date of FMD of SS3.
Week 52 of study
Change From Baseline in PRO2 Scores at Weeks 20, 28, 36, 44 and 52: SS3 Responder Cohort
Ramy czasowe: Baseline, study Weeks 20, 28, 36, 44 and 52
The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain. SS3 Baseline was defined as last non-missing measurement taken prior to date of FMD of SS3.
Baseline, study Weeks 20, 28, 36, 44 and 52
Change From Baseline in PRO2 Scores at Weeks 20, 28, 36, 44 and 52: SS3 Non-Responder Cohort
Ramy czasowe: Baseline, study Weeks 20, 28, 36, 44 and 52
The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain. SS3 Baseline was defined as last non-missing measurement taken prior to date of FMD of SS3.
Baseline, study Weeks 20, 28, 36, 44 and 52
Time to Remission by PRO2 and FCP Concentrations: SS3 Responder Cohort
Ramy czasowe: From first maintenance dose in SS3 until date of clinical remission and FCP normalization or censoring date (maximum up to 42 weeks)
Time to remission by PRO2 and FCP concentrations was defined as time to onset of clinical remission by PRO2 and FCP normalization. Clinical remission by PRO2 was defined as PRO2 score <8. Normalization of FCP was defined as FCP <=150 milligrams per kilogram. The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain. Participants who did not achieve remission or discontinued from study were censored at 7 days after last dose of study drug.
From first maintenance dose in SS3 until date of clinical remission and FCP normalization or censoring date (maximum up to 42 weeks)
Time to Remission by PRO2 and FCP Concentrations: SS3 Non-Responder Cohort
Ramy czasowe: From first maintenance dose in SS3 until date of clinical remission and FCP normalization or censoring date (maximum up to 42 weeks)
Time to remission by PRO2 and FCP concentrations was defined as time to onset of clinical remission by PRO2 and FCP normalization. Clinical remission by PRO2 was defined as PRO2 score <8. Normalization of FCP was defined as FCP <=150 milligrams per kilogram. The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain. Participants who did not achieve remission or discontinued from study were censored at 7 days after last dose of study drug.
From first maintenance dose in SS3 until date of clinical remission and FCP normalization or censoring date (maximum up to 42 weeks)
Time to Response by PRO2 and FCP Concentrations: SS3 Responder Cohort
Ramy czasowe: From first maintenance dose in SS3 until date of clinical response and FCP normalization or censoring date (maximum up to 42 weeks)
Time to response by PRO2 and FCP concentrations: time to onset of PRO2 response and FCP normalization. Clinical response by PRO2: clinical remission by PRO2 or >= 8-point decrease from baseline in PRO2 score. Clinical remission by PRO2: PRO2 score <8. Normalization of FCP: FCP <=150 milligrams per kilogram. The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain. Participants who did not achieve response or discontinued from study were censored at 7 days after last dose of study drug.
From first maintenance dose in SS3 until date of clinical response and FCP normalization or censoring date (maximum up to 42 weeks)
Time to Response by PRO2 and FCP Concentrations: SS3 Non-Responder Cohort
Ramy czasowe: From first maintenance dose in SS3 until date of clinical response and FCP normalization or censoring date (maximum up to 42 weeks)
Time to response by PRO2 and FCP concentrations: time to onset of PRO2 response and FCP normalization. Clinical response by PRO2: clinical remission by PRO2 or >= 8-point decrease from baseline in PRO2 score. Clinical remission by PRO2: PRO2 score <8. Normalization of FCP: FCP <=150 milligrams per kilogram. The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain. Participants who did not achieve response or discontinued from study were censored at 7 days after last dose of study drug.
From first maintenance dose in SS3 until date of clinical response and FCP normalization or censoring date (maximum up to 42 weeks)
Change From Baseline in SES-CD Score at Week 52: SS3 Responder Cohort
Ramy czasowe: Baseline and Week 52 of study
SES-CD was an endoscopic grading system which consisted of composite score based on 4 components: size of ulcers, ulcerated surface, affected surface and presence of narrowing assessed in 5 segments: ileum; right; transverse; left colon and rectum. Size of ulcers score: 0= none, 1= aphthous ulcers, 2=large ulcers and 3=very large ulcers. Ulcerated surface score: 0=none, 1= <10%, 2= 10% - 30% and 3= >30%. Affected surface score: 0=unaffected segment, 1= <50%, 2= 50% - 75%, and 3= >75%. Presence of narrowing score: 0=none, 1=single, can be passed, 2=multiple can be passed, 3=cannot be passed. Total SES CD= sum of each component score for all 5 bowel segments and ranged from 0 (no disease)-60 (severe disease), higher score indicated more severe disease. SS3 Baseline= last non-missing measurement taken prior to date of FMD of SS3.
Baseline and Week 52 of study
Change From Baseline in SES-CD Score at Week 52: SS3 Non-Responder Cohort
Ramy czasowe: Baseline and Week 52 of study
SES-CD was an endoscopic grading system which consisted of composite score based on 4 components: size of ulcers, ulcerated surface, affected surface and presence of narrowing assessed in 5 segments: ileum; right; transverse; left colon and rectum. Size of ulcers score: 0= none, 1= aphthous ulcers, 2=large ulcers and 3=very large ulcers. Ulcerated surface score: 0=none, 1= <10%, 2= 10% - 30% and 3= >30%. Affected surface score: 0=unaffected segment, 1= <50%, 2= 50% - 75%, and 3= >75%. Presence of narrowing score: 0=none, 1=single, can be passed, 2=multiple can be passed, 3=cannot be passed. Total SES CD= sum of each component score for all 5 bowel segments and ranged from 0 (no disease)-60 (severe disease), higher score indicated more severe disease. SS3 Baseline= last non-missing measurement taken prior to date of FMD of SS3.
Baseline and Week 52 of study
Percentage of Participants With Endoscopic Response and Clinical Remission by PRO2 at Week 52: SS3 Responder Cohort
Ramy czasowe: Week 52 of study
Endoscopic response: SES-CD score <=4 and at least 2-point reduction from baseline with no subscore >1 or >=50% decrease from parent study (SS1) baseline in SES-CD. SES-CD had 4 components assessed for 5 bowel segments where, each component score ranged from 0 to 3, higher scores=more severe condition. Total SES CD score was determined by sum of each component score for all 5 bowel segments and ranged from 0-60, higher score=more severe disease. Clinical remission by PRO2: PRO2 score <8. PRO2 was patient-reported outcome measure based on abdominal pain and stool frequency components of CDAI. Abdominal pain graded from 0 (none)-3 (severe) each day for 7 days. Stool frequency was number of liquid or soft stools each day for 7 days. Total PRO2 score calculated as sum of averaged abdominal pain/stool frequency variable scores*weighting factor. PRO2 score had minimum score of 0 and had no upper bound, with higher score indicating more frequent stools and more severe abdominal pain.
Week 52 of study
Percentage of Participants With Endoscopic Response and Clinical Remission by PRO2 at Week 52: SS3 Non-Responder Cohort
Ramy czasowe: Week 52 of study
Endoscopic response: SES-CD score <=4 and at least 2-point reduction from baseline with no subscore >1 or >=50% decrease from parent study (SS1) baseline in SES-CD. SES-CD had 4 components assessed for 5 bowel segments where, each component score ranged from 0 to 3, higher scores=more severe condition. Total SES CD score was determined by sum of each component score for all 5 bowel segments and ranged from 0-60, higher score=more severe disease. Clinical remission by PRO2: PRO2 score <8. PRO2 was patient-reported outcome measure based on abdominal pain and stool frequency components of CDAI. Abdominal pain graded from 0 (none)-3 (severe) each day for 7 days. Stool frequency was number of liquid or soft stools each day for 7 days. Total PRO2 score calculated as sum of averaged abdominal pain/stool frequency variable scores*weighting factor. PRO2 score had minimum score of 0 and had no upper bound, with higher score indicating more frequent stools and more severe abdominal pain.
Week 52 of study
Percentage of Participants With Endoscopic Remission and Clinical Remission by PRO2 at Week 52: SS3 Responder Cohort
Ramy czasowe: Week 52 of study
Endoscopic remission: SES-CD <=4 and at least 2-point reduction from baseline with no sub-score >1. SES-CD comprised of 4 components assessed for 5 bowel segments where, each component score ranged from 0 to 3, higher scores indicated more severe condition. Total SES CD score was determined by sum of each component score for all 5 bowel segments and ranged from 0 to 60, higher score indicated more severe disease. Clinical remission by PRO2 was defined as PRO2 score <8. PRO2 was patient-reported outcome measure based on abdominal pain and stool frequency components of CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. Stool frequency was number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as sum of averaged abdominal pain/stool frequency variable scores*weighting factor. PRO2 score had a minimum score of 0 and had no upper bound, with higher score indicating more frequent stools and more severe abdominal pain.
Week 52 of study
Percentage of Participants With Endoscopic Remission and Clinical Remission by PRO2 at Week 52: SS3 Non-Responder Cohort
Ramy czasowe: Week 52 of study
Endoscopic remission: SES-CD <=4 and at least 2-point reduction from baseline with no sub-score >1. SES-CD comprised of 4 components assessed for 5 bowel segments where, each component score ranged from 0 to 3, higher scores indicated more severe condition. Total SES CD score was determined by sum of each component score for all 5 bowel segments and ranged from 0 to 60, higher score indicated more severe disease. Clinical remission by PRO2 was defined as PRO2 score <8. PRO2 was patient-reported outcome measure based on abdominal pain and stool frequency components of CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. Stool frequency was number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as sum of averaged abdominal pain/stool frequency variable scores*weighting factor. PRO2 score had a minimum score of 0 and had no upper bound, with higher score indicating more frequent stools and more severe abdominal pain.
Week 52 of study
Number of Participants According to Markedly Abnormal Criteria for Electrocardiogram (ECG) Parameters: SS4
Ramy czasowe: Baseline, Weeks 52, and 104 of SS4
Pre-defined markedly abnormal criteria for ECG parameters included: QT interval: >500 (milliseconds [msec]); change from SS4 baseline >30 msec and change from SS4 baseline >60 msec. QT interval corrected using Fridericia's formula (QTcF) (msec): >=450 (male) or >=470 (female) msec; change from SS4 baseline >30 msec; change from SS4 baseline >60 msec. PR interval (msec): >230 msec. Only those ECG parameters in which at least 1 participant in any of the reporting arm had markedly abnormal criteria are reported in this outcome measure. SS4 Baseline was defined as the last non-missing measurement taken up to the date of first dose in the SS4.
Baseline, Weeks 52, and 104 of SS4
Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), TEAEs by Severity and Treatment Related TEAEs: SS3
Ramy czasowe: From first dose of study treatment (Day 1) up to 4 weeks post last dose of study treatment (maximum treatment exposure: 38 weeks; maximum follow-up: 42 weeks)
AE: any untoward medical occurrence that did not necessarily have a causal relationship with treatment. SAE: an AE that met one of the following criteria: resulted in death; was life-threatening; required inpatient or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect or medically significant. AEs were graded by the National Cancer Institute Common Terminology Criteria for AE version 5 where, Grade(G) 1: mild AE; G2: moderate; G3: severe; G4: life-threatening consequences, urgent intervention indicated; G5: death related to AE. AE was considered TEAE if it started or worsened in severity on or after the first dose of study treatment. Treatment related AEs were AEs that were related to the study treatment and relatedness was judged by investigator.
From first dose of study treatment (Day 1) up to 4 weeks post last dose of study treatment (maximum treatment exposure: 38 weeks; maximum follow-up: 42 weeks)
Number of Participants With TEAEs of Special Interest: SS3
Ramy czasowe: From first dose of study treatment (Day 1) up to 4 weeks post last dose of study treatment (maximum treatment exposure: 38 weeks; maximum follow-up: 42 weeks)
The TEAEs of special interest included: cardiovascular events (bradycardia, atrioventricular [AV] conduction delay, and hypertension); macular edema; pulmonary disorders (airflow obstruction [forced expiratory volume in 1 second, and forced vital capacity], decreased gas exchange [diffusing capacity of the lung for carbon monoxide]); infections (severe infections, opportunistic infections, and herpes simplex and herpes zoster); liver injury (liver transaminases elevation, and bilirubin elevation); posterior reversible encephalopathy syndrome; and malignancies. Number of participants with any TEAEs of special interest were reported in this outcome measure.
From first dose of study treatment (Day 1) up to 4 weeks post last dose of study treatment (maximum treatment exposure: 38 weeks; maximum follow-up: 42 weeks)
Number of Participants With Clinically Meaningful Changes in Laboratory Parameters: SS3
Ramy czasowe: From first dose of study treatment (Day 1) up to 4 weeks post last dose of study treatment (maximum treatment exposure: 38 weeks; maximum follow-up: 42 weeks)
Clinically meaningful laboratory abnormalities:Hemoglobin, Hematocrit, Erythrocytes (<0.8*LLN); Ery. Volume, Hemoglobin,Mean Corpuscular HGB Concentration <0.8*LLN or >1.5*LLN;Reticulocytes, Leukocytes, Lymphocytes, Neutrophils, Neutrophils, Basophils, Eosinophils, Monocytes (>1.2*ULN), Prothrombin Time(>1.1*ULN).Clinical Chemistry: Bilirubin, Direct Bilirubin, Indirect Bilirubin (1.5*ULN), Aspartate Aminotransferase, Alanine Aminotransferase, Gamma Glutamyl Transferase, Alkaline Phosphatase (>3.0*ULN); Albumin, Urate (<0.8*LLN and >1.2*ULN; Urea Nitrogen,Creatinine Cholesterol >1.3*ULN; Cholesterol <0.8*LLN or >1.2*LLN, Triglycerides,Potassium,Calcium < 0.9x LLN & >1.1x ULN; Bicarbonate, Glucose, Creatine Kinase. Urinalysis: Glucose, Ketones, Protein, Hemoglobin, Urobilinogen, Bilirubin, Nitrite >=1; Leukocyte Erythrocytes, Leukocytes >=20; Epithelial Cells>=6, Hyaline Cast>1; Bacteria>20. Number of participants with any laboratory abnormality meeting specified criteria is included.
From first dose of study treatment (Day 1) up to 4 weeks post last dose of study treatment (maximum treatment exposure: 38 weeks; maximum follow-up: 42 weeks)
Number of Participants With TEAEs, SAEs, TEAEs by Severity and Treatment Related TEAEs: SS4
Ramy czasowe: From first dose of study treatment (Day 1) up to 4 weeks post last dose of study treatment (maximum treatment exposure: 166.3 weeks; maximum follow-up: 170.3 weeks)
AE: any untoward medical occurrence that did not necessarily have a causal relationship with treatment. SAE: an AE that met one of the following criteria: resulted in death; was life-threatening; required inpatient or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect or medically significant. AEs were graded by the National Cancer Institute Common Terminology Criteria for AE version 5 where, G1: mild AE; G2: moderate; G3: severe; G4: life-threatening consequences, urgent intervention indicated; G5: death related to AE. AE was considered TEAE if it started or worsened in severity on or after the first dose of study treatment. Treatment related AEs were AEs that were related to the study treatment and relatedness was judged by investigator.
From first dose of study treatment (Day 1) up to 4 weeks post last dose of study treatment (maximum treatment exposure: 166.3 weeks; maximum follow-up: 170.3 weeks)
Number of Participants With TEAEs of Special Interest: SS4
Ramy czasowe: From first dose of study treatment (Day 1) up to 4 weeks post last dose of study treatment (maximum treatment exposure: 166.3 weeks; maximum follow-up: 170.3 weeks)
The TEAEs of special interest included: cardiovascular events (bradycardia, AV conduction delay, and hypertension); macular edema; pulmonary disorders (airflow obstruction [forced expiratory volume in 1 second, and forced vital capacity], decreased gas exchange [diffusing capacity of the lung for carbon monoxide]); infections (severe infections, opportunistic infections, and herpes simplex and herpes zoster); liver injury (liver transaminases elevation, and bilirubin elevation); posterior reversible encephalopathy syndrome; and malignancies. Number of participants with any TEAEs of special interest were reported in this outcome measure.
From first dose of study treatment (Day 1) up to 4 weeks post last dose of study treatment (maximum treatment exposure: 166.3 weeks; maximum follow-up: 170.3 weeks)
Number of Participants With Clinically Meaningful Changes in Laboratory Parameters: SS4
Ramy czasowe: From first dose of study treatment (Day 1) up to 4 weeks post last dose of study treatment (maximum treatment exposure: 166.3 weeks; maximum follow-up: 170.3 weeks)
Clinically meaningful laboratory abnormalities:Hemoglobin, Hematocrit, Erythrocytes (<0.8*LLN); Ery. Volume, Hemoglobin,Mean Corpuscular HGB Concentration <0.8*LLN or >1.5*LLN;Reticulocytes, Leukocytes, Lymphocytes, Neutrophils, Neutrophils, Basophils, Eosinophils, Monocytes (>1.2*ULN), Prothrombin Time(>1.1*ULN).Clinical Chemistry: Bilirubin, Direct Bilirubin, Indirect Bilirubin (1.5*ULN), Aspartate Aminotransferase, Alanine Aminotransferase, Gamma Glutamyl Transferase, Alkaline Phosphatase (>3.0*ULN); Albumin, Urate (<0.8*LLN and >1.2*ULN; Urea Nitrogen,Creatinine Cholesterol >1.3*ULN; Cholesterol <0.8*LLN or >1.2*LLN, Triglycerides,Potassium,Calcium < 0.9x LLN & >1.1x ULN; Bicarbonate, Glucose, Creatine Kinase. Urinalysis: Glucose, Ketones, Protein, Hemoglobin, Urobilinogen, Bilirubin, Nitrite >=1; Leukocyte Erythrocytes, Leukocytes >=20; Epithelial Cells>=6, Hyaline Cast>1; Bacteria>20. Number of participants with any laboratory abnormality meeting specified criteria is included.
From first dose of study treatment (Day 1) up to 4 weeks post last dose of study treatment (maximum treatment exposure: 166.3 weeks; maximum follow-up: 170.3 weeks)
Number of Participants According to Markedly Abnormal Criteria for Vital Signs: SS4
Ramy czasowe: Baseline, Weeks 1, 12, 24, 36, 52, 64, 76, 88 and 104 of SS4
Pre-defined markedly abnormal criteria for vital signs included: Systolic blood pressure (millimeters of mercury [mmHg]): low: <=90 mmHg and high: >150 mmHg. Diastolic blood pressure (mmHg): low: <=50 mmHg and high: >90 mmHg. Heart rate (beats per minute [bpm]): low: <40 bpm, <50 bpm and high: >100 bpm. Only those vital signs parameters in which at least 1 participant in any of the reporting arm had markedly abnormal criteria are reported in this outcome measure. SS4 baseline=the last non-missing measurement taken up to the date of first dose in the SS4.
Baseline, Weeks 1, 12, 24, 36, 52, 64, 76, 88 and 104 of SS4
Percentage of Participants With Clinical Remission by CDAI at Weeks 12, 24, 36, 52, 64, 76, 88 and 104: SS4
Ramy czasowe: Weeks 12, 24, 36, 52, 64, 76, 88 and 104 of SS4
Clinical remission was considered as CDAI score <150. CDAI was a composite index consisting of a weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); HCT 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score was calculated as the sum of variable scores*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores indicated more severe disease.
Weeks 12, 24, 36, 52, 64, 76, 88 and 104 of SS4
Percentage of Participants With Clinical Response by CDAI at Weeks 12, 24, 36, 52, 64, 76, 88 and 104: SS4
Ramy czasowe: Weeks 12, 24, 36, 52, 64, 76, 88 and 104 of SS4
Clinical Response was defined as having clinical remission CDAI or >=100-point decrease from baseline in CDAI score where, clinical remission was considered as CDAI <150. CDAI was a composite index consisting of a weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); HCT 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score was calculated as the sum of variable scores*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores indicated more severe disease.
Weeks 12, 24, 36, 52, 64, 76, 88 and 104 of SS4
Percentage of Participants With Clinical Remission by PRO2 at Weeks 12, 24, 36, 52, 64, 76, 88 and 104: SS4
Ramy czasowe: Weeks 12, 24, 36, 52, 64, 76, 88 and 104 of SS4
Clinical remission was defined as PRO2 score <8. The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain.
Weeks 12, 24, 36, 52, 64, 76, 88 and 104 of SS4

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Sponsor

Śledczy

  • Dyrektor Studium: Pfizer CT.gov Call Center, Pfizer

Publikacje i pomocne linki

Osoba odpowiedzialna za wprowadzenie informacji o badaniu dobrowolnie udostępnia te publikacje. Mogą one dotyczyć wszystkiego, co jest związane z badaniem.

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Rzeczywisty)

6 stycznia 2020

Zakończenie podstawowe (Rzeczywisty)

23 kwietnia 2025

Ukończenie studiów (Rzeczywisty)

9 czerwca 2025

Daty rejestracji na studia

Pierwszy przesłany

20 listopada 2019

Pierwszy przesłany, który spełnia kryteria kontroli jakości

20 listopada 2019

Pierwszy wysłany (Rzeczywisty)

21 listopada 2019

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

1 lipca 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

5 czerwca 2026

Ostatnia weryfikacja

1 czerwca 2026

Więcej informacji

Terminy związane z tym badaniem

Inne numery identyfikacyjne badania

  • APD334-202
  • C5041006 (Inny identyfikator: Alias Study Number)
  • 2024-513569-38-00 (Identyfikator rejestru: CTIS (EU))

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

TAK

Opis planu IPD

Firma Pfizer zapewni dostęp do danych poszczególnych uczestników, których dane identyfikacyjne zostały pozbawione elementów umożliwiających identyfikację, oraz związanych z nimi dokumentów badawczych (np. protokół, plan analizy statystycznej (SAP), raport z badania klinicznego (CSR)) na żądanie wykwalifikowanych badaczy i z zastrzeżeniem pewnych kryteriów, warunków i wyjątków. Więcej informacji na temat kryteriów udostępniania danych przez firmę Pfizer oraz procesu ubiegania się o dostęp można znaleźć na stronie: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Tak

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

produkt wyprodukowany i wyeksportowany z USA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj